20. Literaturverzeichnis – Hodentumoren

1. AWMF, AWMF-Regelwerk „Leitlinien“. 1. Auflage 2012Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF)- Ständige Kommission Leitlinien, 2012.

2. Albany, C., Adra, N., Snavely, A.C., Cary, C., Masterson, T.A., Foster, R.S., et.al. Multidisciplinary clinic approach improves overall survival outcomes of patients with metastatic germ-cell tumors, Ann Oncol, 2018. 29(2): p. 341-346.

3. Collette, L., Sylvester, R.J., Stenning, S.P., Fossa, S.D., Mead, G.M., de Wit, R., et.al. Impact of the treating institution on survival of patients with "poor-prognosis" metastatic nonseminoma. European Organization for Research and Treatment of Cancer Genito-Urinary Tract Cancer Collaborative Group and the Medical Research Council Testicular Cancer Working Party, J Natl Cancer Inst, 1999. 91(10): p. 839-46.

4. Vlayen, J., Vrijens, F., Devriese, S., Beirens, K., Van Eycken, E., Stordeur, S., Quality indicators for testicular cancer: a population-based study, Eur J Cancer, 2012. 48(8): p. 1133-40.

5. IGCCCG, International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group, J Clin Oncol, 1997. 15(2): p. 594-603.

6. Cost, N.G., Caldwell, B.T., Adibi, M., Raj, G.V., Sagalowsky, A.I., Margulis, V., Do Referral Patterns in Adolescents and Young Adults with Testicular Cancer Impact Oncologic Outcomes?, J Adolesc Young Adult Oncol, 2016. 5(3): p. 248-53.

7. Jeldres, C., Pham, K.N., Daneshmand, S., Kollmannsberger, C.K., Hayes-Lattin, B.M., Wolff, E., et.al. Association of higher institutional volume with improved overall survival in clinical stage III testicular cancer: Results from the National Cancer Data Base (1998-2011)Journal of Clinical Oncology, ASCO, 2014. 32: p. 4519-4519.

8. Woldu, S.L., Matulay, J.T., Clinton, T.N., Singla, N., Krabbe, L.M., Hutchinson, R.C., et.al. Impact of hospital case volume on testicular cancer outcomes and practice patterns, Urol Oncol, 2018. 36(1): p. 14.e7-14.e15.

9. Capitanio, U., Jeldres, C., Perrotte, P., Isbarn, H., Crepel, M., Cloutier, V., et.al. Population-based study of perioperative mortality after retroperitoneal lymphadenectomy for nonseminomatous testicular germ cell tumors, Urology, 2009. 74(2): p. 373-7.

10. Baniel, J., Foster, R.S., Rowland, R.G., Bihrle, R., Donohue, J.P., Complications of post-chemotherapy retroperitoneal lymph node dissection, J Urol, 1995. 153(3 Pt 2): p. 976-80.

11. EAU, EAU Guidelines on Testicular CancerEuropean Association of Urology, 2018a.

12. NCCN, NCCN Guidelines Version 2.2018 Testicular Cancer, NCCN Clinical Practice Guidelines in Oncology, 2018a. Version 2.2018:

13. SIGN, Management of adult testicular germ cell tumours. A national clinical guideline., Edinburgh, (Scotland): Scottish Intercollegiate Guidelines Network (SIGN), 2011. SIGN publication; no. 124: p. 63.

14. Flechon, A., Tavernier, E., Boyle, H., Meeus, P., Rivoire, M., Droz, J. P., Long-term oncological outcome after post-chemotherapy retroperitoneal lymph node dissection in men with metastatic nonseminomatous germ cell tumour, BJU Int, 2010. 106(6): p. 779-85.

15. Paffenholz, P., Heidegger, I. M., Kuhr, K., Loosen, S. H., Pfister, D., Heidenreich, A., Non-Guideline-concordant Treatment of Testicular Cancer Is Associated With Reduced Relapse-free Survival, Clin Genitourin Cancer, 2017.

16. Schrader, M., Weissbach, L., Hartmann, M., Krege, S., Albers, P., Miller, K., et.al. Burden or relief: do second-opinion centers influence the quality of care delivered to patients with testicular germ cell cancer?, Eur Urol, 2010. 57(5): p. 867-72.

17. Schrader, M., Zengerling, F., Hakenberg, O. W., Protzel, C., [German national second-opinion network for testicular cancer and penile carcinoma: Two sources for evidence-based information], Urologe A, 2016. 55(9): p. 1192-8.

18. Zengerling, F., Krege, S., Schrader, A. J., Schrader, M., [National second opinion network for testicular cancer patients - transferring guidelines into practice!], Aktuelle Urol, 2014. 45(6): p. 454-6.

19. Bertz, J., Buttmann-Schweiger, N., Kraywinkel, K., Epidemiologie bösartiger Hodentumoren in Deutschland, Der Onkologe, 2017. 23: p. 90–96.

20. Behre, H.M., Kliesch, S., Schadel, F., Nieschlag, E., Clinical relevance of scrotal and transrectal ultrasonography in andrological patients, Int J Androl, 1995. 18 Suppl 2: p. 27-31.

21. Dieckmann, K.P., Hartmann, J.T., Classen, J., Ludde, R., Diederichs, M., Pichlmeier, U., Tallness is associated with risk of testicular cancer: evidence for the nutrition hypothesis, Br J Cancer, 2008. 99(9): p. 1517-21.

22. Latif, T., Kold Jensen, T., Mehlsen, J., Holmboe, S. A., Brinth, L., Pors, K., et.al. Semen quality as a predictor of subsequent morbidity: a Danish cohort study of 4,712 men with long-term follow-up, Am J Epidemiol, 2017. 186(8): p. 910-917.

23. Lerro, C.C., McGlynn, K.A., Cook, M.B., A systematic review and meta-analysis of the relationship between body size and testicular cancer, Br J Cancer, 2010. 103(9): p. 1467-74.

24. Olesen, I.A., Andersson, A.M., Aksglaede, L., Skakkebaek, N.E., Rajpert-de Meyts, E., Joergensen, N., et.al. Clinical, genetic, biochemical, and testicular biopsy findings among 1,213 men evaluated for infertility, Fertil Steril, 2017. 107(1): p. 74-82.e7.

25. Raman, J. D., Nobert, C. F., Goldstein, M., Increased incidence of testicular cancer in men presenting with infertility and abnormal semen analysis, J Urol, 2005. 174(5): p. 1819-22; discussion 1822.

26. Ilic, D., Misso, M.L., Screening for testicular cancer, Cochrane Database Syst Rev, 2011. p. 16;(2):CD007853.

27. USPSTF, Screening for testicular cancer: U.S. Preventive Services Task Force reaffirmation recommendation statement, Ann Intern Med, 2011. 154(7): p. 483-6.

28. DIMDI, Systematisches Verzeichnis: Internationale statistische Klassifikationen der Krankheiten und verwandter Gesundheitsprobleme, Deutscher Ärzte-Verlag, 2017. 1. Auflage(ICD-10-GM 2017):

29. RKI, Krebs in Deutschland 2013/2014Robert Koch-Institut, 2017.

30. Ruf, C.G., Isbarn, H., Wagner, W., Fisch, M., Matthies, C., Dieckmann, K.P., Changes in epidemiologic features of testicular germ cell cancer: Age at diagnosis and relative frequency of seminoma are constantly and significantly increasing, Urol Oncol, 2014. 32(1): p. 33.e1-6.

31. Harland, S.J., Cook, P.A., Fossa, S.D., Horwich, A., Parkinson, M.C., Roberts, J.T., et.al. Risk factors for carcinoma in situ of the contralateral testis in patients with testicular cancer. An interim report, Eur Urol, 1993. 23(1): p. 115-8; discussion 119.

32. Ghazarian, A.A., Trabert, B., Graubard, B.I., Schwartz, S.M., Altekruse, S.F., McGlynn, K.A, Incidence of testicular germ cell tumors among US men by census region., Cancer, 2015. 121(23): p. 4181-4189.

33. Znaor, A., Lortet-Tieulent, J., Jemal, A., Bray, F., International variations and trends in testicular cancer incidence and mortality, Eur Urol, 2014. 65(6): p. 1095-106.

34. Mikuz, G., [Testicular cancer - a matter of geography? Epidemiology and etiopathogenesis of germ cell tumors], Pathologe, 2014. 35(3): p. 211-7.

35. Stang, A., Bray, F., Dieckmann, K.P., Lortet-Tieulent, J., Rusner, C., Mortality of testicular cancer in East and West Germany 20 years after reunification: a gap not closed yet, Urol Int, 2015. 95(2): p. 160-166.

36. Kvammen, O., Myklebust, T. A., Solberg, A., Moller, B., Klepp, O. H., Fossa, S. D., et.al. Long-term relative survival after diagnosis of testicular germ cell tumor, Cancer Epidemiol Biomarkers Prev, 2016. 25(5): p. 773-9.

37. Banerji, J.S., Odem-Davis, K., Wolff, E.M., Nichols, C.R., Porter, C.R., Patterns of care and survival outcomes for malignant sex cord stromal testicular cancer: results from the national cancer data base., J Urol, 2016. 196(4): p. 1117-1122.

38. Conkey, D.S., Howard, G.C., Grigor, K.M., McLaren, D.B., Kerr, G.R., Testicular sex cord-stromal tumours: the Edinburgh experience 1988-2002, and a review of the literature, Clin Oncol (R Coll Radiol), 2005. 17(5): p. 322-7.

39. Dieckmann, K.P., Pichlmeier, U., Clinical epidemiology of testicular germ cell tumors, World J Urol, 2004. 22(1): p. 2-14.

40. Cook, M.B., Akre, O., Forman, D., Madigan, M.P., Richiardi, L., McGlynn, K.A., A systematic review and meta-analysis of perinatal variables in relation to the risk of testicular cancer--experiences of the son, Int. J. Epidemiol., 2010. 39: p. 1605-1616.

41. Lip, S.Z., Murchison, L.E., Cullis, P.S., Govan, L., Carachi, R., A meta-analysis of the risk of boys with isolated cryptorchidism developing testicular cancer in later life, Arch Dis Child, 2013. 98(1): p. 20-6.

42. Giwercman, A., Grindsted, J., Hansen, B., Jensen, O.M., Skakkebaek, N.E., Testicular cancer risk in boys with maldescended testis: a cohort study., Urol, 1987. 138(5): p. 1214-6.

43. Moller, H., Prener, A., Skakkebaek, N. E., Testicular cancer, cryptorchidism, inguinal hernia, testicular atrophy, and genital malformations: case-control studies in Denmark, Cancer Causes Control, 1996. 7(2): p. 264-74.

44. Abratt, R.P., Reddi, V.B., Sarembock, L.A., Testicular cancer and cryptorchidism, Br J Urol, 1992. 70(6): p. 656-9.

45. Batata, M.A., Chu, F.C., Hilaris, B.S., Whitmore, W.F., Golbey, R.B., Testicular cancer in cryptorchids., Cancer, 1982. 49(5): p. 1023-1030.

46. Pike, M.C., Chilvers, C., Peckham, M.J., Effect of age at orchidopexy on risk of testicular cancer, Lancet, 1986. 1(8492): p. 1246-8.

47. Banks, K., Tuazon, E., Berhane, K., Koh, C.J., De Filippo, R.E., Chang, A., et.al. Cryptorchidism and testicular germ cell tumors: comprehensive meta-analysis reveals that association between these conditions diminished over time and is modified by clinical characteristics, Front Endocrinol (Lausanne), 2012. 3: p. 182.

48. Pettersson, A., Richiardi, L., Nordenskjold, A., Kaijser, M., Akre, O., Age at surgery for undescended testis and risk of testicular cancer, N Engl J Med, 2007. 356(18): p. 1835-41.

49. Mai, P.L., Friedlander, M., Tucker, K., Phillips, K.A., Hogg, D., Jewett, M.A., et.al. The International Testicular Cancer Linkage Consortium: A clinicopathologic descriptive analysis of 461 familial malignant testicular germ cell tumor kindred., Urol Oncol, 2010. 28(5): p. 492-499.

50. Kharazmi, E., Hemminki, K., Pukkala, E., Sundquist, K., Tryggvadottir, L., Tretli, S., et.al. Cancer risk in relatives of testicular cancer patients by histology type and age at diagnosis: a joint study from five nordic countries, Eur Urol, 2015. 68(2): p. 283-289.

51. Litchfield, K., Shipley, J., Turnbull, C., Common variants identified in genome-wide association studies of testicular germ cell tumour: an update, biological insights and clinical application, Andrology, 2015. 3(1): p. 34-46.

52. Greene, M.H., Mai, P.L., Loud, J.T., Pathak, A., Peters, J.A., Mirabello, L., et.al. Familial testicular germ cell tumors (FTGCT) - overview of a multidisciplinary etiologic study, Andrology, 2015. 3(1): p. 47-58.

53. Levy, M., Hall, D., Sud, A., Law, P., Litchfield, K., Dudakia, D., et.al. Mendelian randomisation analysis provides no evidence for a relationship between adult height and testicular cancer risk, Andrology, 2017. 5(5): p. 914-922.

54. Tan, I.B., Ang, K.K., Ching, B.C., Mohan, C., Toh, C.K., Tan, M.H., Testicular microlithiasis predicts concurrent testicular germ cell tumors and intratubular germ cell neoplasia of unclassified type in adults: a meta-analysis and systematic review, Cancer, 2010. 116(19): p. 4520-4532.

55. Marte, A., Pintozzi, L., Cretì, G., Chiesa, P.L., Renzo, D.D., Gasparella, M., et.al. Long-term follow-up of testicular microlithiasis in children and adolescents: multicenter prospective cohort study of the Italian society of pediatric urology, Eur J Pediatr Surg, 2017. 27(2): p. 155-160.

56. Wang, T., Liu, L., Luo, J., Liu, T., Wei, A., A meta-analysis of the relationship between testicular microlithiasis and incidence of testicular cancer, Urol J, 2015. 12(2): p. 2057-2064.

57. Patel, K.V., Navaratne, S., Bartlett, E., Clarke, J.L., Muir, G.H., Sellars, M.E., et.al. Testicular microlithiasis: is sonographic surveillance necessary? Single centre 14 year experience in 442 patients with testicular microlithiasis, Ultraschall Med, 2016. 37(1): p. 68-73.

58. van Casteren, N.J., Looijenga, L.H., Dohle, G.R., Testicular microlithiasis and carcinoma in situ overview and proposed clinical guideline, Int J Androl, 2009. 32(4): p. 279-87.

59. ESUR, Testicular microlithiasis imaging and follow-up: guidelines of the ESUR scrotal imaging subcommittee, Eur Radiol, 2015. 25: p. 323-330.

60. Pedersen, M. R., Rafaelsen, S. R., Moller, H., Vedsted, P., Osther, P. J., Testicular microlithiasis and testicular cancer: review of the literature, Int Urol Nephrol, 2016. 48(7): p. 1079-86.

61. Callaghan, R.C., Allebeck, P., Akre, O., McGlynn, K.A., Sidorchuk, A., Cannabis Use and Incidence of Testicular Cancer: A 42-Year Follow-up of Swedish Men between 1970 and 2011, Cancer Epidemiol Biomarkers Prev, 2017. 26(11): p. 1644-1652.

62. Gurney, J., Shaw, C., Stanley, J., Signal, V., Sarfati, D., Cannabis exposure and risk of testicular cancer: a systematic review and meta-analysis, BMC Cancer, 2015. 15: p. 897.

63. Strohsnitter, W.C., Noller, K.L., Hoover, R.N., Robboy, S.J., Palmer, J.R., Titus-Ernstoff, L., et.al. Cancer risk in men exposed in utero to diethylstilbestrol, J Natl Cancer Inst, 2001. 93(7): p. 545-551.

64. Skakkebaek, N.E., Possible carcinoma in situ of the testis., Lancet, 1972. ii: p. 516-517.

65. Bueno, A.T.P., Capelasso, V.L., Pacheco, R.L., Latorraca, C.O.C., Castria, T.B., Pachito, D.V., et.al. What do Cochrane systematic reviews say about the clinical effectiveness of screening and diagnostic tests for cancer?, Sao Paulo Med J, 2017. 135(4): p. 401-410.

66. Albers, P., Albrecht, W., Algaba, F., Bokemeyer, C., Cohn-Cedermark, G., Fizazi, K., et.al. EAU Guideline on testicular cancer, European Association of Urology 2017, 2017.

67. Gilligan, T.D., Seidenfeld, J., Basch, E.M., Einhorn, L.H., Fancher, T., Smith, D.C., et.al. American Society of Clinical Oncology Clinical Practice Guideline on uses of serum tumor markers in adult males with germ cell tumors, J Clin Oncol, 2010. 28(20): p. 3388-404.

68. de Souza, K.W., dos Reis, P.E., Gomes, I.P., de Carvalho, E.C., [Prevention strategies for testicular and penile cancer: an integrative review], Rev Esc Enferm USP, 2011. 45(1): p. 277-82.

69. Rovito, M. J., Cavayero, C., Leone, J. E., Harlin, S., Interventions promoting Testicular Self-Examination (TSE) Performance: a systematic review, Am J Mens Health, 2015. 9(6): p. 506-18.

70. Saab, M.M., Landers, M., Hegarty, J., Promoting Testicular Cancer Awareness and Screening: A Systematic Review of Interventions, Cancer Nurs, 2016. 39(6): p. 473-487.

71. Moch, H., Cubilla, A. L., Humphrey, P. A., Reuter, V. E., Ulbright, T. M., The 2016 WHO classification of tumours of the urinary system and male genital organs-part A: renal, penile, and testicular tumours, Eur Urol, 2016. 70(1): p. 93-105.

72. Mikuz, G., [Germ cell and sex cord-stromal tumors of the testis : WHO classification 2016], Pathologe, 2017. 38(3): p. 209-220.

73. Lorch, A., Albers, P., Beyer, J., Cathomas, R., Oing, C., Souchon, R., et.al. Keimzelltumoren des Mannes. Leitlinie der DGHO. URL: https://www.onkopedia.com/de/onkopedia/guidelines/keimzelltumoren-des-mannes/@@view/pdf/index.pdf. Zugriff am 14.11.2017, 2016.

74. DIMDI, Internationale Klassifikation der Krankheiten für die Onkologie (ICD-O)Deutsches Institut für Medizinische Dokumentation und Information (DIMDI), 2013.

75. Germa-Lluch, J.R., Garcia del Muro, X., Maroto, P., Paz-Ares, L., Arranz, J.A., Guma, J., et.al. Clinical pattern and therapeutic results achieved in 1490 patients with germ-cell tumours of the testis: the experience of the Spanish Germ-Cell Cancer Group (GG), Eur Urol, 2002. 42(6): p. 553-62; discussion 562-3.

76. Moul, J.W., Timely diagnosis of testicular cancer, Urol Clin North Am, 2007. 34(2): p. 109-17.

77. KCE, Tombal, B., Vlayen, J., Stordeur, S., De Meerleer, G., Gil, T., Renard, L., Rorive, S., Rottey, S., Salmon, I., Schrijvers, D., Villeirs, G. Wetenschappelijke ondersteuning van het College voor Oncologie: een update van de nationale richtlijn voor testiskanker, Good Clinical Practice (GCP). Brussel: Federaal Kenniscentrum voor de Gezondheidszorg (KCE), 2010. p. KCE Reports 142A. D/2010/10.273/72.

78. Zhao, J.Y., Ma, X.L., Li, Y.Y., Zhang, B.L., Li, M.M., Ma, X.L., et.al. Diagnostic accuracy of 18F-FDG-PET in patients with testicular cancer: a meta-analysis, Asian Pac J Cancer Prev, 2014. 15(8): p. 3525-31.

79. El Sanharawi, I., Correas, J. M., Glas, L., Ferlicot, S., Izard, V., Ducot, B., et.al. Non-palpable incidentally found testicular tumors: Differentiation between benign, malignant, and burned-out tumors using dynamic contrast-enhanced MRI, Eur J Radiol, 2016. 85(11): p. 2072-2082.

80. Akdogan, B., Divrik, R. T., Tombul, T., Yazici, S., Tasar, C., Zorlu, F., et.al. Bilateral testicular germ cell tumors in Turkey: increase in incidence in last decade and evaluation of risk factors in 30 patients, J Urol, 2007. 178(1): p. 129-33; discussion 133.

81. Campobasso, D., Ferretti, S., Frattini, A., Synchronous bilateral testis cancer: clinical and oncological management, Contemp Oncol (Pozn), 2017. 21(1): p. 70-76.

82. Coogan, C.L., Foster, R.S., Simmons, G.R., Tognoni, P.G., Roth, B.J., Donohue, J.P., Bilateral testicular tumors: management and outcome in 21 patients, Cancer, 1998. 83(3): p. 547-52.

83. Winter, T.C., Kim, B., Lowrance, W.T., Middleton, W.D., Testicular microlithiasis: what should you recommend?, AJR Am J Roentgenol, 2016. 206(6): p. 1164-9.

84. Yacoub, J.H., Oto, A., Allen, B.C., Coakley, F.V., Friedman, B., Hartman, M.S., et.al. ACR appropriateness criteria staging of testicular malignancy, J Am Coll Radiol, 2016. 13(10): p. 1203-1209.

85. See, W.A., Hoxie, L., Chest staging in testis cancer patients: imaging modality selection based upon risk assessment as determined by abdominal computerized tomography scan results, J Urol, 1993. 150(3): p. 874-8.

86. Coursey Moreno, C., Small, W.C., Camacho, J.C., Master, V., Kokabi, N., Lewis, M., et.al. Testicular tumors: what radiologists need to know--differential diagnosis, staging, and management, Radiographics, 2015. 35(2): p. 400-15.

87. Ellis, J.H., Bies, J.R., Kopecky, K.K., Klatte, E.C., Rowland, R.G., Donohue, J.P., Comparison of NMR and CT imaging in the evaluation of metastatic retroperitoneal lymphadenopathy from testicular carcinoma, J Comput Assist Tomogr, 1984. 8(4): p. 709-19.

88. Sohaib, S.A., Koh, D.M., Barbachano, Y., Parikh, J., Husband, J.E., Dearnaley, D.P., et.al. Prospective assessment of MRI for imaging retroperitoneal metastases from testicular germ cell tumours, Clin Radiol, 2009. 64(4): p. 362-7.

89. Poon, R., Poon, R. and the Program in Evidence-Based Care Disease Site Group Reviewers. PET Six-Month Monitoring Report 2015-2, Cancer Care Ontario (CCO), 2016.

90. Wild, C., Patera, N., Küllinger, R., Narath, M., PET/PET-CT Evidenz zum Bedarf und Planung (bei onkologischen Indikationen), Wien: Ludwig Boltzmann Institut für Health Technology Assessment, 2015. HTA Projektbericht Nr. 77:

91. Alberta-Health-Services, Cancer guidelines: Testicular germ cell tumours, CancerControl Alberta, 2016. Clinical practice guideline; no. GU-001, Version 7(Provincial Genitourinary Tumour Team):

92. Takizawa, A., Kawai, K., Kawahara, T., Kojima, T., Maruyama, S., Shinohara, N., et.al. The usefulness of testosterone administration in identifying false-positive elevation of serum human chorionic gonadotropin in patients with germ cell tumor, J Cancer Res Clin Oncol, 2018. 144(1): p. 109-115.

93. Dieckmann, K.P., Radtke, A., Spiekermann, M., Balks, T., Matthies, C., Becker, P., et.al. Serum levels of microRNA miR-371a-3p: a sensitive and specific new biomarker for germ cell tumours, Eur Urol, 2017. 71(2): p. 213-220.

94. Radtke, A., Cremers, J. F., Kliesch, S., Riek, S., Junker, K., Mohamed, S. A., et.al. Can germ cell neoplasia in situ be diagnosed by measuring serum levels of microRNA371a-3p?, J Cancer Res Clin Oncol, 2017. 143(11): p. 2383-2392.

95. ESMO, Testicular seminoma and non-seminoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, 2013. 24 Suppl 6: p. vi125-32.

96. Dieckmann, K.P., Kulejewski, M., Pichlmeier, U., Loy, V., Diagnosis of contralateral testicular intraepithelial neoplasia (TIN) in patients with testicular germ cell cancer: systematic two-site biopsies are more sensitive than a single random biopsy, Eur Urol, 2007. 51(1): p. 175-83; discussion 183-5.

97. Giannarini, G., Dieckmann, K. P., Albers, P., Heidenreich, A., Pizzocaro, G., Organ-sparing surgery for adult testicular tumours: a systematic review of the literature, Eur Urol, 2010. 57(5): p. 780-90.

98. EAU, EAU Guidelines on Testicular CancerEuropean Association of Urology, 2018a.

99. Petersen, P.M., Giwercman, A., Daugaard, G., Rorth, M., Petersen, J.H., Skakkeaek, N.E., et.al. Effect of graded testicular doses of radiotherapy in patients treated for carcinoma-in-situ in the testis, J Clin Oncol, 2002. 20(6): p. 1537-43.

100. Sedlmayer, F., Holtl, W., Kozak, W., Hawliczek, R., Gebhart, F., Gerber, E., et.al. Radiotherapy of testicular intraepithelial neoplasia (TIN): a novel treatment regimen for a rare disease, Int J Radiat Oncol Biol Phys, 2001. 50(4): p. 909-13.

101. Dieckmann, K.P., Wilken, S., Loy, V., Matthies, C., Kleinschmidt, K., Bedke, J., et.al. Treatment of testicular intraepitelial neoplasia (intratubular germ cell neoplasia unspecified) with local radiotherapy or with platinum-based chemotherapy: A survey of the German Testicular Cancer Study Group., Ann Oncol, 2013b. 24(5): p. 1332-1337.

102. Heidenreich, A., Weissbach, L., Holtl, W., Albers, P., Kliesch, S., Kohrmann, K. U., et.al. Organ sparing surgery for malignant germ cell tumor of the testis, J Urol, 2001. 166(6): p. 2161-5.

103. Kliesch, S., Thomaidis, T., Schutte, B., Puhse, G., Kater, B., Roth, S., et.al. Update on the diagnostic safety for detection of testicular intraepithelial neoplasia (TIN), Apmis, 2003. 111(1): p. 70-4; discussion 75.

104. Richenberg J, Belfield J, Ramchandani P, Rocher L, Freeman S, Tsili AC, et.al. Testicular microlithiasis imaging and follow-up: guidelines of the ESUR scrotal imaging subcommittee, Eur Radiol, 2015. 25: p. 323-330.

105. DGGG, DGU, DGRM, Fertility preservation for patients with malignant disease. Guideline of the DGGG, DGU and DGRM (S2k-Level, AWMF Registry No. 015/082. http://www.awmf.org/uploads/tx_szleitlinien/015-082l_S2k_Fertilitaetserhaltung-bei-onkologischen-Therapien_2017-12.pdf (Zugriff am 12.12.2017), DKG Eigenverlag, 2017.

106. Djaladat, H., Burner, E., Parikh, P.M., Beroukhim Kay, D., Hays, K., The association between testis cancer and semen abnormalities before orchiectomy: A Systematic Review, J Adolesc Young Adult Oncol, 2014. 3(4): p. 153-159.

107. Rives, N., Perdrix, A., Hennebicq, S., Saias-Magnan, J., Melin, M. C., Berthaut, I., et.al. The semen quality of 1158 men with testicular cancer at the time of cryopreservation: results of the French National CECOS Network, J Androl, 2012. 33(6): p. 1394-401.

108. Suzuki, K., Shin, T., Shimomura, Y., Iwahata, T., Okada, H., Spermatogenesis in tumor-bearing testes in germ cell testicular cancer patients, Hum Reprod, 2015. 30(12): p. 2853-8.

109. van Casteren, N.J., Boellaard, W.P., Romijn, J.C., Dohle, G.R., Gonadal dysfunction in male cancer patients before cytotoxic treatment, Int J Androl, 2010. 33(1): p. 73-9.

110. Williams, D.H., Karpman, E., Sander, J.C., Spiess, P.E., Pisters, L.L., Lipshultz, L.I., Pretreatment semen parameters in men with cancer, J Urol, 2009. 181(2): p. 736-40.

111. van der Kaaij, M.A., Heutte, N., van Echten-Arends, J., Raemaekers, J.M., Carde, P., Noordijk, E.M., et.al. Sperm quality before treatment in patients with early stage Hodgkin's lymphoma enrolled in EORTC-GELA Lymphoma Group trials, Haematologica, 2009. 94(12): p. 1691-7.

112. Kliesch, S., Behre, H. M., Jurgens, H., Nieschlag, E., Cryopreservation of semen from adolescent patients with malignancies, Med Pediatr Oncol, 1996. 26(1): p. 20-7.

113. Kliesch, S., Kamischke, A., Cooper, TG., Nieschlag, E., Kryokonservierung menschlicher Spermien zur Zeugungsreserve. In: Nieschlag E, Behre HM, Nieschlag S, Hrsg. Andrologie: Grundlagen und Klinik der reproduktiven Gesundheit des Mannes. Springer Berlin Heidelberg, 2009. p. 515-31.

114. Kliesch, S., Bergmann, M., Hertle, L., Nieschlag, E., Behre, H. M., Semen parameters and testicular pathology in men with testicular cancer and contralateral carcinoma in situ or bilateral testicular malignancies, Hum Reprod, 1997. 12(12): p. 2830-2835.

115. Lampe, H., Horwich, A., Norman, A., Nicholls, J., Dearnaley, D. P., Fertility after chemotherapy for testicular germ cell cancers, J Clin Oncol, 1997. 15(1): p. 239-45.

116. Classen, J., Dieckmann, K., Bamberg, M., Souchon, R., Kliesch, S., Kuehn, M., et.al. Radiotherapy with 16 Gy may fail to eradicate testicular intraepithelial neoplasia: preliminary communication of a dose-reduction trial of the German Testicular Cancer Study Group, Br J Cancer, 2003. 88(6): p. 828-31.

117. Classen, J., Schmidberger, H., Meisner, C., Souchon, R., Sautter-Bihl, L., Sauer, R., et.al. Radiotherapy for stages IIA/B testicular seminoma: final report of a prospective multicenter clinical trial, J Clin Oncol, 2003a. 21(6): p. 1101-6.

118. Dieckmann, K.P., Contralateral biopsies in patients with testicular germ-cell tumour-nuisance or new sense?, Ann Oncol, 2015a. 26(4): p. 620-1.

119. Zhang, Z., Shao, S., Meistrich, M. L., Irradiated mouse testes efficiently support spermatogenesis derived from donor germ cells of mice and rats, J Androl, 2006. 27(3): p. 365-75.

120. Meistrich, M.L., Effects of chemotherapy and radiotherapy on spermatogenesis in humans, Fertil Steril, 2013. 100(5): p. 1180-6.

121. Silber, S.J., The use of epididymal sperm for the treatment of male infertility, Baillieres Clin Obstet Gynaecol, 1997. 11(4): p. 739-52.

122. Heidenreich, A., Albers, P., Hartmann, M., Kliesch, S., Kohrmann, K. U., Krege, S., et.al. Complications of primary nerve sparing retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell tumors of the testis: experience of the German Testicular Cancer Study Group, J Urol, 2003. 169(5): p. 1710-4.

123. Steiner, H., Zangerl, F., Stohr, B., Granig, T., Ho, H., Bartsch, G., et.al. Results of bilateral nerve sparing laparoscopic retroperitoneal lymph node dissection for testicular cancer, J Urol, 2008. 180(4): p. 1348-52; discussion 1352-3.

124. Heidenreich, A., Pfister, D., Witthuhn, R., Thuer, D., Albers, P., Postchemotherapy retroperitoneal lymph node dissection in advanced testicular cancer: radical or modified template resection, Eur Urol, 2009. 55(1): p. 217-24.

125. Pettus, J.A., Carver, B.S., Masterson, T., Stasi, J., Sheinfeld, J., Preservation of ejaculation in patients undergoing nerve-sparing postchemotherapy retroperitoneal lymph node dissection for metastatic testicular cancer, Urology, 2009. 73(2): p. 328-31; discussion 331-2.

126. EAU, EAU Guidelines on Male InfertilityEuropean Association of Urology, 2018b.

127. Wittekind, C., TNM Klassifikation Maligner Tumoren, Wiley-VCH Verlag Weinheim, Deutschland, 2017. 8. Auflage:

128. Kollmannsberger, C., Tandstad, T., Bedard, P.L., Cohn-Cedermark, G., Chung, P.W., Jewett, M.A., et.al. Patterns of relapse in patients with clinical stage I testicular cancer managed with active surveillance, J Clin Oncol, 2015. 33(1): p. 51-7.

129. Kier, M.G., Lauritsen, J., Mortensen, M.S., Bandak, M., Andersen, K.K., Hansen, M.K., et.al. Prognostic factors and treatment results after bleomycin, etoposide, and cisplatin in germ cell cancer: a population-based study, Eur Urol, 2017. 71(2): p. 290-298.

130. Albers, P., Siener, R., Kliesch, S., Weissbach, L., Krege, S., Sparwasser, C., et.al. Risk factors for relapse in clinical stage I nonseminomatous testicular germ cell tumors: results of the German Testicular Cancer Study Group Trial, J Clin Oncol, 2003. 21(8): p. 1505-12.

131. Daugaard, G., Gundgaard, M.G., Mortensen, M.S., Agerbaek, M., Holm, N.V., Rorth, M., et.al. Surveillance for stage I nonseminoma testicular cancer: outcomes and long-term follow-up in a population-based cohort, J Clin Oncol, 2014. 32(34): p. 3817-23.

132. Dong, P., Liu, Z.W., Li, X.D., Li, Y.H., Yao, K., Wu, S., et.al. Risk factors for relapse in patients with clinical stage I testicular nonseminomatous germ cell tumors, Med Oncol, 2013. 30(1): p. 494.

133. Li, X., Guo, S., Wu, Z., Dong, P., Li, Y., Zhang, Z., et.al. Surveillance for patients with clinical stage I nonseminomatous testicular germ cell tumors, World J Urol, 2015. 33(9): p. 1351-7.

134. Howard, S.A., Gray, K.P., O'Donnell, E.K., Fennessy, F.M., Beard, C.J., Sweeney, C.J., Craniocaudal retroperitoneal node length as a risk factor for relapse from clinical stage I testicular germ cell tumor, AJR Am J Roentgenol, 2014. 203(4): p. W415-20.

135. Williams, S.B., Kacker, R., Winston, D., Bahnson, E., Steele, G.S., Richie, J.P., Predictors of positive retroperitoneal lymph nodes in patients with high risk testicular cancer, J Urol, 2011. 186(6): p. 2245-8.

136. Nicolai, N., Miceli, R., Necchi, A., Biasoni, D., Catanzaro, M., Milani, A., et.al. Retroperitoneal lymph node dissection with no adjuvant chemotherapy in clinical stage I nonseminomatous germ cell tumours: long-term outcome and analysis of risk factors of recurrence, Eur Urol, 2010. 58(6): p. 912-8.

137. Zengerling, F., Kunath, F., Jensen, K., Ruf, C., Schmidt, S., Spek, A., Prognostic factors for tumor recurrence in patients with clinical stage I seminoma undergoing surveillance - a systematic review, Urol Oncol, 2017. pii: S1078-1439(17)30331-9:

138. Chung, P., Daugaard, G., Tyldesley, S., Atenafu, E.G., Panzarella, T., Kollmannsberger, C., et.al. Evaluation of a prognostic model for risk of relapse in stage I seminoma surveillance, Cancer Med, 2015. 4(1): p. 155-60.

139. Mortensen, M.S., Lauritsen, J., Gundgaard, M.G., Agerbaek, M., Holm, N.V., Christensen, I.J., et.al. A nationwide cohort study of stage I seminoma patients followed on a surveillance program, Eur Urol, 2014. 66(6): p. 1172-8.

140. Boormans, J.L., Mayor de Castro, J., Marconi, L., Yuan, Y., Laguna Pes, M.P., Bokemeyer, C., et.al. Testicular tumour size and rete testis invasion as prognostic factors for the risk of relapse of clinical stage I seminoma testis patients under surveillance: a systematic review by the Testicular Cancer Guidelines Panel, Eur Urol, 2017. 73: p. 394–405.

141. Arai, E., Nakagawa, T., Wakai-Ushijima, S., Fujimoto, H., Kanai, Y., DNA methyltransferase 3B expression is associated with poor outcome of stage I testicular seminoma, Histopathology, 2012. 60(6b): p. E12-8.

142. Hatakeyama, S., Kyan, A., Yamamoto, H., Okamoto, A., Sugiyama, N., Suzuki, Y., et.al. Core 2 N-acetylglucosaminyltransferase-1 expression induces aggressive potential of testicular germ cell tumor, Int J Cancer, 2010. 127(5): p. 1052-9.

143. Albers, P., Ulbright, T.M., Albers, J., Miller, G.A., Orazi, A., Crabtree, W.N., et.al. Tumor proliferative activity is predictive of pathological stage in clinical stage A nonseminomatous testicular germ cell tumors, J Urol, 1996. 155(2): p. 579-86.

144. Lo, K.C., Wong, C., Emond, J., Aprikian, A.G., Scrotal orchiectomy for a large testicular seminoma, Can J Urol, 2001. 8(2): p. 1234-6.

145. Herrinton, L.J., Brox, T., Greenland, S., Finkle, W. D., Cattolica, E., Shoor, S., Regarding: a cohort study of systemic and local complications following implantation of testicular prostheses, Ann Epidemiol, 2003. 13(1): p. 73-7.

146. Dieckmann, K.P., Anheuser, P., Schmidt, S., Soyka-Hundt, B., Pichlmeier, U., Schriefer, P., et.al. Testicular prostheses in patients with testicular cancer - acceptance rate and patient satisfaction, BMC Urol, 2015b. 15(16): p. 1-7.

147. Robinson, R., Tait, C. D., Clarke, N. W., Ramani, V. A., Is it safe to insert a testicular prosthesis at the time of radical orchidectomy for testis cancer: an audit of 904 men undergoing radical orchidectomy, BJU Int, 2016. 117(2): p. 249-52.

148. Balk, E.M., Earley, A., Avendano, E.A., Raman, G., Long-term health outcomes in women with silicone gel breast implants: a systematic review, Ann Intern Med, 2016. 164(3): p. 164-75.

149. Lipworth, L., Tarone, R. E., McLaughlin, J. K., Silicone breast implants and connective tissue disease: an updated review of the epidemiologic evidence, Ann Plast Surg, 2004. 52(6): p. 598-601.

150. Bang, A.K., Petersen, J.H., Petersen, P.M., Andersson, A.M., Daugaard, G., Jørgensen, N., Testosterone production is better preserved after 16 than 20 Gray irradiation treatment against testicular carcinoma in situ cells., Int J Radiat Oncol Biol Phys, 2009. 75(3): p. 672-676.

151. Brabrand, S., Fosså, S.D., Cvancarova, M., Axcrona, U., Lehne, G., Probability of metachronous testicular cancer in patients with biopsy-proven intratubular germ cell neoplasia depends on first-time treatment of germ cell cancer., J Clin Oncol, 2012. 30(32): p. 4004-4010.

152. Dieckmann, K.P., Skakkebaek, N.E., Carcinoma in situ of the testis: A review of biological and clinical features., Int J Cancer, 1999. 83: p. 815-822.

153. Spiller, C.M., Bowles, J., Germ cell neoplasia in situ: The precursor cell for invasive germ cell tumors of the testis, 2017. 86: p. 22-25.

154. Berney, D.M., Looijenga, L., Idrees, M., Oosterhuis, J.W., Rajpert-De Meyts, E., Ulbright, T.M., et.al. Germ Cell Neoplasia In Situ (GCNIS). Evolution of the current nomenclature for testicular pre-invasive germ cell malignancy., Histopathology, 2016. 69(1): p. 7-10.

155. Hoei-Hansen, C.E., Rajpert-De Meyts, E., Daugaard, G., Skakkebaek, N.E., Carcinoma in situ testis, the progenitor of testicular germ cell tumours: a clinical review., Ann Oncol, 2005. 16(6): p. 863-8.

156. Rorth, M., Rajpert-De Meyts, E., Andersson, L., Dieckmann, K.P., Fossa, S.D., Grigor, K.M., et.al. Carcinoma in situ in the testis, Scand J Urol Nephrol, 2000. suppl. 205: p. 166-186.

157. Skakkebaek, N.E., Berthelsen, J.G., Visfeldt, J., Clinical aspects of testicular carcinoma in situ., Int J Androl, 1981. suppl. 4: p. 153-162.

158. Albers, P., Albrecht, W., Algaba, F., Bokemeyer, C., Cohn-Cedermark, G., Fizazi, K., et.al. Guidelines on Testicular Cancer: 2015 Update., Eur. Urol., 2015. 68: p. 1054-1068.

159. Mortensen, M.S., Gundgaard, M.G., Daugaard, G., Treatment options for carcinoma in situ testis., Int J Androl, 2011. 34(4 pt 2): p. e32-e36.

160. Petersen, P.M., Giwercman, A., Hansen, S.W., Berthelsen, J.G., Daugaard, G., Rorth, M., et.al. Impaired testicular function in patients with carcinoma-in-situ of the testis, J Clin Oncol, 1999. 17(1): p. 173-179.

161. Skakkebaek, N.E., Rajpert-De Meyts, E., Buck Louis, G.M., Toppari, J., Andersson, A.M., Eisenberg, M.L., et.al. Male reproductive disorders and fertility trends: influences of environment and genetic susceptibility, Physiol Rev, 2016. 96(1): p. 55-97.

162. Dieckmann, K.P., Loy, V., Paternity of a patient with testicular seminoma and contralateral testicular intraepithelial neoplasia, Int J Androl, 1993. 16: p. 143-146.

163. Heidenreich, A., Vorreuther, R., Neubauer, S., Zumbe, J., Engelmann, U.H., Paternity in patients with bilateral testicular germ cell tumors., Eur Urol, 1997b. 31(2): p. 246-8.

164. Houlgatte, A., De La Taille, A., Fournier, R., Goluboff, E.T., Camporo, P., Houdelette, P., Paternity in a patient with seminoma and carcinoma in situ in a solitary testis treated by partial orchidectomy., BJU Int, 1999. 84(4): p. 374-5.

165. Andreassen, K.E., Grotmol, T., Cvancarova, M.S., Johannesen, T.B., Fossa, S.D., Risk of metachronous contralateral testicular germ cell tumors: A population-based study of 7,102 Norwegian patients (1953-2007), Int. J. Cancer, 2011. 129(12): p. 2867-2874.

166. Dieckmann, K.P., Anheuser, P., Sattler, F., Von Kügelgen, T., Matthies, C., Ruf, C.G., Sequential bilateral testicular tumours presenting with intervals of 20 years and more, BMC Urol, 2013a. 13(1): p. 71.

167. Kier, M.G., Lauritsen, J., Almstrup, K., Mortensen, M.S., Toft, B.G., Rajpert-De Meyts, E., et.al. Screening for carcinoma in situ in the contralateral testicle in patients with testicular cancer: a population-based study (DaTeCa 03 study), Ann Oncol, 2015. 26(4): p. 737-742.

168. Christensen, T. B., Daugaard, G., Geertsen, P.F., von der Maase, H., Effect of chemotherapy on carcinoma in situ of the testis., Ann Oncol, 1998. 9: p. 657-660.

169. Fossa, S.D., Aass, N., Heilo, A., Daugaard, G., Skakkebaek, N.E., Stenwig, A.E., et.al. Testicular carcinoma in situ in patients with extragonadal germ-cell tumours: the clinical role of pretreatment biopsy., Ann Oncol, 2003a. 14(9): p. 1412-1418.

170. Hentrich, M., Weber, N., Bergsdorf, T., Liedl, B., Hartenstein, R., Gerl, A., Management and outcome of bilateral testicular germ cell tumors: Twenty-five year experience in Munich., Acta Oncol, 2005. 44(6): p. 529-36.

171. Pamenter, B., De Bono, J.S., Brown, I.L., Nandini, M., Kaye, S.B., Russell, J.M., et.al. Bilateral testicular cancer: a preventable problem? Experience from a large cancer centre., BJU Int, 2003. 92(1): p. 43-46.

172. Zequi, S.D., da Costa, W.H., Santana, T.B., Favaretto, R.L., Sacomani, C.A., Guimaraes, G.C., Bilateral testicular germ cell tumours: a systematic review, BJU Int, 2012. 110(8): p. 1102-1109.

173. Hartmann, J.T., Fossa, S.D., Nichols, C.R., Droz, J.P., Horwich, A., Gerl, A., et.al. Incidence of metachronous testicular cancer in patients with extragonadal germ cell tumors, J. Natl. Cancer Inst., 2001. 93(22): p. 1733-1738.

174. Dieckmann, K.P., Loy, V., Intratesticular effects of cisplatin-based chemotherapy, Eur Urol, 1995. 28(1): p. 25-30.

175. Ramani, V.A., Grey, B.R., Addla, S.K., Dunham, M.P., Sangar, V.K., Clarke, N.W., Histological outcome of delayed orchidectomy after primary chemotherapy for metastatic germ cell tumour of the testis, Clin Oncol (R Coll Radiol), 2008. 20(3): p. 247-252.

176. Ramsey, S., Kerr, G., Howard, G.C., Donat, R., Orchidectomy after primary chemotherapy for metastatic testicular cancer, Urol Int, 2013. 91(4): p. 439-444.

177. Giwercman, A., von der Maase, H., Rorth, M., Skakkebaek, N.E., Current concepts of radiation treatment of carcinoma in situ of the testis., World J Urol, 1994. 12(3): p. 125-30.

178. Dieckmann, K.P., Lauke, H., Michl, U., Winter, E., Loy, V., Testicular germ cell cancer despite previous local radiotherapy to the testis, Eur Urol, 2002. 41(6): p. 643-649.

179. Tandstad, T., Solberg, A., Håkansson, U., Stahl, O., Haugnes, H.S., Oldenburg, J., et.al. Bilateral testicular germ cell tumors in patients treated for clinical stage I non-seminoma within two risk-adapted SWENOTECA protocols., Acta Oncol., 2014. 54(4): p. 493-499.

180. Chau, C., Cathomas, R., Wheater, M., Klingbiel, D., Fehr, M., Bennett, J., et.al. Treatment outcome and patterns of relapse following adjuvant carboplatin for stage I testicular seminomatous germ-cell tumour: results from a 17-year UK experience, Ann Oncol, 2015. 26(9): p. 1865-70.

181. Detti, B., Scoccianti, S., Villari, D., Cipressi, S., Sardaro, A., Simontacchi, G., et.al. Management of stage l testicular seminoma over a period of 49 years, Onkologie, 2011. 34(10): p. 510-4.

182. Haugnes, H.S., Solhaug, O., Stenberg, J., Hjelle, L.V., Bremnes, R.M., Seminoma patients treated at a minor oncological department during 1986-2010: treatment and outcome, Anticancer Res, 2014. 34(8): p. 4253-60.

183. Kollmannsberger, C., Tyldesley, S., Moore, C., Chi, K.N., Murray, N., Daneshmand, S., et.al. Evolution in management of testicular seminoma: population-based outcomes with selective utilization of active therapies, Ann Oncol, 2011. 22(4): p. 808-14.

184. Serdar, L., Canyilmaz, E., Topcu, T. O., Sahbaz, A., Memis, Y., Soydemir, G., et.al. Adjuvant radiotherapy in stage 1 seminoma: Evaluation of prognostic factors and results of survival, J Cancer Res Ther, 2015. 11(2): p. 313-8.

185. Soper, M.S., Hastings, J.R., Cosmatos, H.A., Slezak, J.M., Wang, R., Lodin, K., Observation versus adjuvant radiation or chemotherapy in the management of stage I seminoma: clinical outcomes and prognostic factors for relapse in a large US cohort, Am J Clin Oncol, 2014. 37(4): p. 356-9.

186. Tandstad, T., Smaaland, R., Solberg, A., Bremnes, R. M., Langberg, C. W., Laurell, A., et.al. Management of seminomatous testicular cancer: a binational prospective population-based study from the Swedish Norwegian Testicular Cancer Study Group, J Clin Oncol, 2011. 29(6): p. 719-25.

187. Tandstad, T., Stahl, O., Hakansson, U., Wahlqvist, R., Klepp, O., Cavallin-Stahl, E., et.al. The SWENOTECA group: A good example of continuous binational and multidisciplinary collaboration for patients with testicular cancer in Sweden and Norway, Scand J Urol, 2016. 50(1): p. 9-13.

188. Cummins, S., Yau, T., Huddart, R., Dearnaley, D., Horwich, A., Surveillance in stage I seminoma patients: a long-term assessment, European Urology, 2010. 57(4): p. 673-8.

189. Kamba, T., Kamoto, T., Okubo, K., Teramukai, S., Kakehi, Y., Matsuda, T., et.al. Outcome of different post-orchiectomy management for stage I seminoma: Japanese multi-institutional study including 425 patients, Int J Urol, 2010. 17(12): p. 980-7.

190. Leung, E., Warde, P., Jewett, M., Panzarella, T., O'Malley, M., Sweet, J., et.al. Treatment burden in stage I seminoma: a comparison of surveillance and adjuvant radiation therapy, BJU Int, 2013. 112(8): p. 1088-95.

191. Aparicio, J., Maroto, P., del Muro, X.G., Guma, J., Sanchez-Munoz, A., Margeli, M., et.al. Risk-adapted treatment in clinical stage I testicular seminoma: the third Spanish Germ Cell Cancer Group study, J Clin Oncol, 2011. 29(35): p. 4677-81.

192. Krege, S., Beyer, J., Souchon, R., Albers, P., Albrecht, W., Algaba, F., et.al. European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCG): part I, Eur Urol, 2008a. 53(3): p. 478-96.

193. Krege, S., Beyer, J., Souchon, R., Albers, P., Albrecht, W., Algaba, F., et.al. European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): part II, Eur Urol, 2008b. 53(3): p. 497-513.

194. Mead, G.M., Fossa, S.D., Oliver, R.T., Joffe, J.K., Huddart, R.A., Roberts, J.T., et.al. Randomized trials in 2466 patients with stage I seminoma: patterns of relapse and follow-up, J Natl Cancer Inst, 2011. 103(3): p. 241-9.

195. Tandstad, T., Stahl, O., Dahl, I., Glimelius, H. S., Haugnes, A., Karlsdottir, C. W., et.al. The ABC-study: A randomized phase III study comparing one course of adjuvant bleomycin, etoposide, and cisplatin (BEP) and one course of carboplatin AUC7 in clinical stage I seminomatous testicular cancer, J Clin Oncol, 2017. 35((15_suppl): TPS4593-TPS4593.):

196. Warde, P., Specht, L., Horwich, A., Oliver, T., Panzarella, T., Gospodarowicz, M., et.al. Prognostic factors for relapse in stage I seminoma managed by surveillance: a pooled analysis, J Clin Oncol, 2002. 20(22): p. 4448-52.

197. Dieckmann, K.P., Dralle-Filiz, I., Matthies, C., Heinzelbecker, J., Bedke, J., Ellinger, J., et.al. Testicular seminoma clinical stage 1: treatment outcome on a routine care level, J Cancer Res Clin Oncol, 2016. 142(7): p. 1599-607.

198. Ondrusova, M., Ondrus, D., Miskovska, V., Kajo, K., Szoldova, K., Usakova, V., et.al. Management of clinical stage I testicular seminoma: active surveillance versus adjuvant chemotherapy, Int Urol Nephrol, 2015. 47(7): p. 1143-7.

199. Steiner, H., Scheiber, K., Berger, A. P., Rein, P., Hobisch, A., Aufderklamm, J., et.al. Retrospective multicentre study of carboplatin monotherapy for clinical stage I seminoma, BJU Int, 2011. 107(7): p. 1074-9.

200. Groll, R.J., Warde, P., Jewett, M.A., A comprehensive systematic review of testicular germ cell tumor surveillance, Crit Rev Oncol Hematol, 2007. 64(3): p. 182-97.

201. Argirovic, D.J., Germ cell testicular tumors in clinical stage A and normal values of serum tumor mark-ers post-orchiectomy: the experience in the management of 300 consecutive patients, J buon, 2005. 10(2): p. 195-200.

202. Koutsoukos, K., Tzannis, K., Christodoulou, C., Karavasilis, V., Bakoyiannis, C., Makatsoris, T., et.al. Two cycles of adjuvant carboplatin in stage I seminoma: 8-year experience by the Hellenic Cooperative Oncology Group (HECOG), World J Urol, 2016. 34(6): p. 853-7.

203. Reiter, W.J., Brodowicz, T., Alavi, S., Zielinski, C.C., Kozak, W., Maier, U., et.al. Twelve-year experience with two courses of adjuvant single-agent carboplatin therapy for clinical stage I seminoma https://www.ncbi.nlm.nih.gov/pubmed/11134201, J Clin Oncol, 2001. 19(1): p. 101-4.

204. Cathomas, R., Klingbiel, D., Geldart, T.R., Mead, G.M., Ellis, S., Wheater, M., et.al. Relevant risk of carboplatin underdosing in cancer patients with normal renal function using estimated GFR: lessons from a stage I seminoma cohort, Ann Oncol, 2014. 25(8): p. 1591-7.

205. Diminutto, A., Basso, U., Maruzzo, M., Morelli, F., De Giorgi, U., Perin, A., et.al. Adjuvant Carboplatin Treatment in 115 Patients With Stage I Seminoma: Retrospective Multicenter Survey, Clin Genitourin Cancer, 2016. 14(2): p. e161-9.

206. Powles, T., Robinson, D., Shamash, J., Moller, H., Tranter, N., Oliver, T., The long-term risks of adjuvant carboplatin treatment for stage I seminoma of the testis, Ann Oncol, 2008. 19(3): p. 443-7.

207. Terbuch, A., Posch, F., Annerer, L. M., Bauernhofer, T., Pichler, M., Szkandera, J., et.al. Long-term cardiovascular complications in stage I seminoma patients, Clin Transl Oncol, 2017. 19(11): p. 1400-1408.

208. Bilici, A., Ozturk, T., Turkmen, E., Odabas, H., Cihan, S., Selcukbiricik, F., et.al. Treatment preferences in stage IA and IB testicular seminoma: multicenter study of Anatolian Society of Medical Oncology, World J Urol, 2015. 33(10): p. 1613-22.

209. Bamberg, M., Schmidberger, H., Meisner, C., Radiotherapy for stage I, IIA/B testicular seminoma, Int J Cancer, 1999a. 83: p. 823-27.

210. Bamberg, M., Schmidberger, H., Meisner, C., Classen, J., Souchon, R., Weinknecht, S., et.al. Radiotherapy for stages I and IIA/B testicular seminoma, Int J Cancer, 1999b. 83(6): p. 823-7.

211. Jones, W.G., Fossa, S.D., Mead, G.M., Roberts, J.T., Sokal, M., Horwich, A., et.al. Randomized trial of 30 versus 20 Gy in the adjuvant treatment of stage I Testicular Seminoma: a report on Medical Research Council Trial TE18, European Organisation for the Research and Treatment of Cancer Trial 30942 (ISRCTN18525328), J Clin Oncol, 2005. 23(6): p. 1200-8.

212. Mortensen, M.S., Bandak, M., Kier, M. G., Lauritsen, J., Agerbaek, M., Holm, N.V., et.al. Surveillance versus adjuvant radiotherapy for patients with high-risk stage I seminoma, Cancer, 2017. 123(7): p. 1212-1218.

213. Jones, G., Arthurs, B., Kaya, H., Macdonald, K., Qin, R., Fairbanks, R.K., et.al. Overall survival analysis of adjuvant radiation versus observation in stage I testicular seminoma: a surveillance, epidemiology, and end results (SEER) analysis, Am J Clin Oncol, 2013. 36(5): p. 500-4.

214. Oliver, R.T., Mason, M.D., Mead, G.M., von der Maase, H., Rustin, G.J., Joffe, J.K., et.al. Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomised trial, Lancet, 2005. 366(9482): p. 293-300.

215. Oliver, R.T., Mead, G.M., Rustin, G.J., Joffe, J.K., Aass, N., Coleman, R., et.al. Randomized trial of carboplatin versus radiotherapy for stage I seminoma: mature results on relapse and contralateral testis cancer rates in MRC TE19/EORTC 30982 study (ISRCTN27163214), J Clin Oncol, 2011. 29(8): p. 957-62.

216. Hallemeier, C.L., Choo, R., Davis, B.J., Leibovich, B.C., Costello, B.A., Pisansky, T.M., Excellent long-term disease control with modern radiotherapy techniques for stage I testicular seminoma--the Mayo Clinic experience, Urol Oncol, 2014. 32(1): p. 24.e1-6.

217. Gamulin, M., Grgic, M., Bisof, V., Side effects of adjuvant radiotherapy in men with testicular seminoma stage I, Arh Hig Rada Toksikol, 2011. 62(3): p. 235-41.

218. Horwich, A., Fossa, S. D., Huddart, R., Dearnaley, D.P., Stenning, S., Aresu, M., et.al. Second cancer risk and mortality in men treated with radiotherapy for stage I seminoma, Br J of Cancer, 2014. 110(1): p. 256-63.

219. Kier, M.G., Hansen, M.K., Lauritsen, J., Mortensen, M.S., Bandak, M., Agerbaek, M., et.al. Second malignant neoplasms and cause of death in patients with germ cell cancer: a Danish nationwide cohort study, JAMA Oncol, 2016. 2(12): p. 1624-1627.

220. Lewinshtein, D., Gulati, R., Nelson, P. S., Porter, C. R., Incidence of second malignancies after external beam radiotherapy for clinical stage I testicular seminoma, BJU Int, 2012. 109(5): p. 706-12.

221. Bentzen, S.M., Constine, L.S., Deasy, J.O., Eisbruch, A., Jackson, A., Marks, L.B., et.al. Quantitative analyses of normal tissue effects in the clinic (QUANTEC): an introduction to the scientific issues, Int J Radiat Oncol Biol Phys, 2010. 76(3 Suppl): p. S3-9.

222. Read, G., Stenning, S. P., Cullen, M. H., Parkinson, M. C., Horwich, A., Kaye, S. B., et.al. Medical Research Council prospective study of surveillance for stage I testicular teratoma. Medical Research Council Testicular Tumors Working Party, J Clin Oncol, 1992. 10(11): p. 1762-8.

223. Oliver, R.T., Ong, J., Shamash, J., Ravi, R., Nagund, V., Harper, P., et.al. Long-term follow-up of Anglian Germ Cell Cancer Group surveillance versus patients with Stage 1 nonseminoma treated with adjuvant chemotherapy, Urology, 2004. 63(3): p. 556-61.

224. Maroto, P., Garcia del Muro, X., Aparicio, J., Paz-Ares, L., Arranz, J. A., Guma, J., et.al. Multicentre risk-adapted management for stage I non-seminomatous germ cell tumours, Ann Oncol, 2005. 16(12): p. 1915-20.

225. Albers, P., Siener, R., Krege, S., Schmelz, H.U., Dieckmann, K.P., Heidenreich, A., et.al. Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I Nonseminomatous testicular germ cell tumors: AUO trial AH 01/94 by the German Testicular Cancer Study Group, J Clin Oncol, 2008. 26(18): p. 2966-72.

226. Ondrus, D., Kajo, K., Stastna, V., Ondrusova, M., Controversies in the management of clinical stage I nonseminomatous germ cell testicular cancer, Klin Onkol, 2015. 28(2): p. 112-5.

227. Kollmannsberger, C., Moore, C., Chi, K.N., Murray, N., Daneshmand, S., Gleave, M., et.al. Non-risk-adapted surveillance for patients with stage I nonseminomatous testicular germ-cell tumors: diminishing treatment-related morbidity while maintaining efficacy, Ann Oncol, 2010a. 21(6): p. 1296-301.

228. Sturgeon, J.F., Moore, M.J., Kakiashvili, D.M., Duran, I., Anson-Cartwright, L.C., Berthold, D.R., et.al. Non-risk-adapted surveillance in clinical stage I nonseminomatous germ cell tumors: the Princess Margaret Hospital's experience, Eur Urol, 2011. 59(4): p. 556-62.

229. Bohlen, D., Borner, M., Sonntag, R.W., Fey, M.F., Studer, U.E., Long-term results following adjuvant chemotherapy in patients with clinical stage I testicular nonseminomatous malignant germ cell tumors with high risk factors, J Urol, 1999. 161(4): p. 1148-52.

230. Heidenreich, A., Schenkmann, N. S., Sesterhenn, I. A., Mostofi, F. K., McCarthy, W. F., Heidenreich, B., et.al. Immunohistochemical expression of Ki-67 to predict lymph node involvement in clinical stage I nonseminomatous germ cell tumors, J Urol, 1997a. 158(2): p. 620-5.

231. Klepp, O., Dahl, O., Flodgren, P., Stierner, U., Olsson, A. M., Oldbring, J., et.al. Risk-adapted treatment of clinical stage 1 non-seminoma testis cancer, Eur J Cancer, 1997. 33(7): p. 1038-44.

232. Madej, G., Pawinski, A., Risk-related adjuvant chemotherapy for stage I non-seminoma of the testis, Clin Oncol (R Coll Radiol), 1991. 3(5): p. 270-2.

233. Ondrus, D., Matoska, J., Belan, V., Kausitz, J., Goncalves, F., Hornak, M., Prognostic factors in clinical stage I nonseminomatous germ cell testicular tumors: rationale for different risk-adapted treatment, Eur Urol, 1998. 33(6): p. 562-6.

234. Pont, J., Holtl, W., Kosak, D., Machacek, E., Kienzer, H., Julcher, H., et.al. Risk-adapted treatment choice in stage I nonseminomatous testicular germ cell cancer by regarding vascular invasion in the primary tumor: a prospective trial, J Clin Oncol, 1990. 8(1): p. 16-20.

235. Sogani, P.C., Perrotti, M., Herr, H.W., Fair, W.R., Thaler, H.T., Bosl, G., Clinical stage I testis cancer: long-term outcome of patients on surveillance, J Urol, 1998. 159(3): p. 855-8.

236. Beyer, J., Albers, P., Altena, R., Aparicio, J., Bokemeyer, C., Busch, J., et.al. Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer, Ann Oncol, 2013. 24(4): p. 878-88.

237. Studer, U.E., Fey, M.F., Calderoni, A., Adjuvant chemotherapy after orchiectomy in high-risk patients with clinical stage I nonseminomatous testicular cancer, Eur Urol, 1993. 23(4): p. 444-449.

238. Cullen, M.H., Stenning, S.P., Parkinson, M.C., Fossa, S.D., Kaye, S.B., Horwich, A.H., et.al. Short-course adjuvant chemotherapy in high-risk stage I nonseminomatous germ cell tumors of the testis: a Medical Research Council report, J Clin Oncol, 1996. 14(4): p. 1106-13.

239. Pont, J., Albrecht, W., Postner, G., Sellner, F., Angel, K., Holtl, W., Adjuvant chemotherapy for high-risk clinical stage I nonseminomatous testicular germ cell cancer: long-term results of a prospective trial, J Clin Oncol, 1996. 14(2): p. 441-8.

240. Chevreau, C., Mazerolles, C., Soulie, M., Long-term efficacy of two cycles of BEP regimen in high-risk stage I nonseminomatous testicular germ cell tumors with embryonal carcinoma and/or vascular invasion., Eur Urol, 2004. 46: p. 209-214.

241. Bamias, A., Aravantinos, G., Kastriotis, I., Alivizatos, G., Anastasiou, I., Christodoulou, C., et.al. Report of the long-term efficacy of two cycles of adjuvant bleomycin/etoposide/cisplatin in patients with stage I testicular nonseminomatous germ-cell tumors (NSGCT): a risk adapted protocol of the Hellenic Cooperative Oncology Group, Urol Oncol, 2011. 29(2): p. 189-93.

242. Tandstad, T., Cohn-Cedermark, G., Dahl, O., Stierner, U., Cavallin-Stahl, E., Bremnes, R. M., et.al. Long-term follow-up after risk-adapted treatment in clinical stage 1 (CS1) nonseminomatous germ-cell testicular cancer (NSGCT) implementing adjuvant CVB chemotherapy. A SWENOTECA study, Ann Oncol, 2010. 21(9): p. 1858-63.

243. Tandstad, T., Stahl, O., Hakansson, U., Dahl, O., Haugnes, H. S., Klepp, O. H., et.al. One course of adjuvant BEP in clinical stage I nonseminoma mature and expanded results from the SWENOTECA group, Ann Oncol, 2014. 25(11): p. 2167-72.

244. Fan, G., Zhang, L., Yi, L., Jiang, Z.Q., Ke, Y., Wang, X.S., et.al. Comparative effectiveness of risk-adapted surveillance vs retroperitoneal lymph node dissection in clinical stage I nonseminomatous germ cell testicular cancer: a retrospective follow-up study of 81 patients, Asian Pac J Cancer Prev, 2015. 16(8): p. 3267-72.

245. Neyer, M., Peschel, R., Akkad, T., Springer-Stohr, B., Berger, A., Bartsch, G., et.al. Long-term results of laparoscopic retroperitoneal lymph-node dissection for clinical stage I nonseminomatous germ-cell testicular cancer, J Endourol, 2007. 21(2): p. 180-3.

246. Albers, P., Albrecht, W., Algaba, F., Bokemeyer, C., Cohn-Cedermark, G., Fizazi, K., et.al. EAU Guidelines on Testicular Cancer. European Association of Urology, 2018.

247. Vidal, A.D., Thalmann, G.N., Karamitopoulou-Diamantis, E., Fey, M.F., Studer, U.E., Long-term outcome of patients with clinical stage I high-risk nonseminomatous germ-cell tumors 15 years after one adjuvant cycle of bleomycin, etoposide, and cisplatin chemotherapy, Ann Oncol, 2015. 26(2): p. 374-7.

248. Weiner, A.B., Pearce, S.M., Eggener, S.E., Management trends for men with early-stage nonseminomatous germ cell tumors of the testicle: An analysis of the National Cancer Database, Cancer, 2017. 123(2): p. 245-252.

249. Yap, S.A., Yuh, L.M., Evans, C.P., Dall'Era, M.A., Wagenaar, R.M., Cress, R., et.al. Evolving patterns of care in the management of stage I non-seminomatous germ cell tumors: data from the California Cancer Registry, World J Urol, 2017. 35(2): p. 277-283.

250. Tandstad, T., Dahl, O., Cohn-Cedermark, G., Cavallin-Stahl, E., Stierner, U., Solberg, A., et.al. Risk-adapted treatment in clinical stage I nonseminomatous germ cell testicular cancer: the SWENOTECA management program, J Clin Oncol, 2009. 27(13): p. 2122-8.

251. Culine, S., Theodore, C., Terrier-Lacombe, M.J., Droz, J.P., Primary chemotherapy in patients with nonseminomatous germ cell tumors of the testis and biological disease only after orchiectomy, J Urol, 1996. 155(4): p. 1296-8.

252. Davis, B.E., Herr, H.W., Fair, W.R., Bosl, G.J., The management of patients with nonseminomatous germ cell tumors of the testis with serologic disease only after orchiectomy, J Urol, 1994. 152(1): p. 111-3; discussion 114.

253. Rajpert-De Meyts, E., McGlynn, K. A., Okamoto, K., Jewett, M. A., Bokemeyer, C., Testicular germ cell tumours, Lancet, 2016. 387(10029): p. 1762-74.

254. Ahmed, K.A., Wilder, R. B., Stage IIA and IIB testicular seminoma treated postorchiectomy with radiation therapy versus other approaches: a population-based analysis of 241 patients, Int Braz J Urol, 2015. 41(1): p. 78-85.

255. Domont, J., Massard, C., Patrikidou, A., Bossi, A., de Crevoisier, R., Rose, M., et.al. A risk-adapted strategy of radiotherapy or cisplatin-based chemotherapy in stage II seminoma, Urol Oncol, 2013. 31(5): p. 697-705.

256. Paly, J.J., Lin, C.C., Gray, P.J., Hallemeier, C.L., Beard, C., Sineshaw, H., et.al. Management and outcomes of clinical stage IIA/B seminoma: Results from the National Cancer Data Base 1998-2012, Pract Radiat Oncol, 2016. 6(6): p. e249-e258.

257. Hallemeier, C.L., Pisansky, T.M., Davis, B.J., Choo, R., Long-term outcomes of radiotherapy for stage II testicular seminoma--the Mayo Clinic experience, Urol Oncol, 2013. 31(8): p. 1832-8.

258. Giannatempo, P., Greco, T., Mariani, L., Nicolai, N., Tana, S., Fare, E., et.al. Radiotherapy or chemotherapy for clinical stage IIA and IIB seminoma: a systematic review and meta-analysis of patient outcomes, Ann Oncol, 2015. 26(4): p. 657-68.

259. Borski, A.A., Proceedings: Diagnosis, staging, and natural history of testicular tumors, Cancer, 1973. 32(5): p. 1202-5.

260. Busch, F.M., Sayegh, E.S., Chenault, O.W., Jr., Some uses of lymphangiography in the management of testicular tumors, J Urol, 1965. 93(4): p. 490-5.

261. Ray, B., Hajdu, S. I., Whitmore, W. F. Jr., Proceedings: Distribution of retroperitoneal lymph node metastases in testicular germinal tumors, Cancer, 1974. 33(2): p. 340-8.

262. Brierley, J.D., Gospodarowicz, M.K., Wittekind, C., TNM Classification of Malignant Tumours. ed. 8 Oxford, UK: Wiley Blackwell; 2017, 2017.

263. Kreydin, E. I., Barrisford, G. W., Feldman, A. S., Preston, M. A., Testicular cancer: what the radiologist needs to know, AJR Am J Roentgenol, 2013. 200(6): p. 1215-25.

264. Krug, B., Heidenreich, A., Dietlein M., et al., Lymphknotenstaging maligner testikulärer Keimzelltumoren, 1999. 171: p. 87–94.

265. Leibovitch, I., Foster, R. S., Kopecky, K. K., Albers, P., Ulbright, T. M., Donohue, J. P., Identification of clinical stage A nonseminomatous testis cancer patients at extremely low risk for metastatic disease: a combined approach using quantitive immunohistochemical, histopathologic, and radiologic assessment, J Clin Oncol, 1998. 16(1): p. 261-8.

266. Leibovitch, L., Foster, R. S., Kopecky, K. K., Donohue, J. P., Improved accuracy of computerized tomography based clinical staging in low stage nonseminomatous germ cell cancer using size criteria of retroperitoneal lymph nodes, J Urol, 1995. 154(5): p. 1759-63.

267. Milosevic, M.F., Gospodarowicz, M., Warde, P., Management of testicular seminoma, Semin Surg Oncol, 1999. 17(4): p. 240-9.

268. Patterson, H., Norman, A. R., Mitra, S. S., Nicholls, J., Fisher, C., Dearnaley, D. P., et.al. Combination carboplatin and radiotherapy in the management of stage II testicular seminoma: comparison with radiotherapy treatment alone, Radiother Oncol, 2001. 59(1): p. 5-11.

269. von der Maase, H., Do we have a new standard of treatment for patients with seminoma stage IIA and stage IIB?, Radiother Oncol, 2001. 59(1): p. 1-3.

270. Wortel, R.C., Ghidey Alemayehu, W., Incrocci, L., Orchiectomy and radiotherapy for stage I-II testicular seminoma: a prospective evaluation of short-term effects on body image and sexual function, J Sex Med, 2015. 12(1): p. 210-8.

271. Tookman, L., Rashid, S., Matakidou, A., Phillips, M., Wilson, P., Ansell, W., et.al. Carboplatin AUC 10 for IGCCCG good prognosis metastatic seminoma, Acta Oncol, 2013. 52(5): p. 987-93.

272. Glaser, S.M., Vargo, J.A., Balasubramani, G.K., Beriwal, S., Stage II testicular seminoma: patterns of care and survival by treatment strategy, Clin Oncol (R Coll Radiol), 2016. 28(8): p. 513-21.

273. Garcia-del-Muro, X., Maroto, P., Guma, J., Sastre, J., Lopez Brea, M., Arranz, J.A., et.al. Chemotherapy as an alternative to radiotherapy in the treatment of stage IIA and IIB testicular seminoma: a Spanish Germ Cell Cancer Group Study, J Clin Oncol, 2008. 26(33): p. 5416-21.

274. ESMO, Schmoll, H.J., Jordan, K., Huddart, R., Pes, M.P., Horwich, A., Fizazi, K., Kataja, V. Testicular seminoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol, 2010. 21 Suppl 5: p. v140-6.

275. NCCN, https://www.nccn.org/, 2016.

276. Wood, L., Kollmannsberger, C., Jewett, M., Chung, P., Hotte, S., O'Malley, M., et.al. Canadian consensus guidelines for the management of testicular germ cell cancer, Can Urol Assoc J, 2010. 4(2): p. e19-38.

277. ESMO, ESMO Consensus Conference on testicular germ cell cancer: diagnosis, treatment and follow-up, Ann Oncol, 2018. 29(8): p. 1658-1686.

278. Detti, B., Livi, L., Scoccianti, S., Gacci, M., Lapini, A., Cai, T., et.al. Management of stage ll testicular seminoma over a period of 40 years, Urol Oncol, 2009. 27(5): p. 534-8.

279. Krege, S., Boergermann, C., Baschek, R., Hinke, A., Pottek, T., Kliesch, S., et.al. Single agent carboplatin for CS IIA/B testicular seminoma. A phase II study of the German Testicular Cancer Study Group (GTCSG), Ann Oncol, 2006. 17(2): p. 276-80.

280. Schmoll, H.J., Souchon, R., Krege, S., Albers, P., Beyer, J., Kollmannsberger, C., et.al. European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG), Ann Oncol, 2004. 15(9): p. 1377-99.

281. Souchon, R., Krege, S., Schmoll, H. J., Albers, P., Beyer, J., Bokemeyer, C., et.al. [Interdisciplinary consensus on diagnosis and therapy of testicular tumors. Results of an update conference based on evidence-based medicine. German Testicular Cancer study Group (GTCSG)], Strahlenther Onkol, 2000. 176(9): p. 388-405.

282. Lieng, H., Chung, P., Lam, T., Warde, P., Craig, T., Testicular seminoma: Scattered radiation dose to the contralateral testis in the modern era, Pract Radiat Oncol, 2018. 8(2): p. e57-e62.

283. Hauptmann, M., Borge Johannesen, T., Gilbert, E.S., Stovall, M., van Leeuwen, F.E., Rajaraman, P., et.al. Increased pancreatic cancer risk following radiotherapy for testicular cancer, Br J Cancer, 2016. 115(7): p. 901-8.

284. Hauptmann, M., Fossa, S.D., Stovall, M., van Leeuwen, F.E., Johannesen, T.B., Rajaraman, P., et.al. Increased stomach cancer risk following radiotherapy for testicular cancer, Br J Cancer, 2015. 112(1): p. 44-51.

285. Stephenson, A.J., Bosl, G.J., Bajorin, D.F., Stasi, J., Motzer, R.J., Sheinfeld, J., Retroperitoneal lymph node dissection in patients with low stage testicular cancer with embryonal carcinoma predominance and/or lymphovascular invasion, J Urol, 2005. 174(2): p. 557-60; discussion 560.

286. Stephenson, A. J., Bosl, G. J., Motzer, R. J., Bajorin, D. F., Stasi, J. P., Sheinfeld, J., Nonrandomized comparison of primary chemotherapy and retroperitoneal lymph node dissection for clinical stage IIA and IIB nonseminomatous germ cell testicular cancer, J Clin Oncol, 2007. 25(35): p. 5597-602.

287. Williams, S.D., Stablein, D.M., Einhorn, L.H., Muggia, F.M., Weiss, R.B., Donohue, J.P., et.al. Immediate adjuvant chemotherapy versus observation with treatment at relapse in pathological stage II testicular cancer, N Engl J Med, 1987. 317(23): p. 1433-8.

288. Sheinfeld, J., Motzer, R. J., Rabbani, F., McKiernan, J., Bajorin, D., Bosl, G. J., Incidence and clinical outcome of patients with teratoma in the retroperitoneum following primary retroperitoneal lymph node dissection for clinical stages I and IIA nonseminomatous germ cell tumors, J Urol, 2003. 170(4 Pt 1): p. 1159-62.

289. Motzer, R.J., Sheinfeld, J., Mazumdar, M., Bajorin, D.F., Bosl, G.J., Herr, H., et.al. Etoposide and cisplatin adjuvant therapy for patients with pathologic stage II germ cell tumors, J Clin Oncol, 1995. 13(11): p. 2700-4.

290. Kondagunta, G.V., Sheinfeld, J., Mazumdar, M., Mariani, T. V., Bajorin, D., Bacik, J., et.al. Relapse-free and overall survival in patients with pathologic stage II nonseminomatous germ cell cancer treated with etoposide and cisplatin adjuvant chemotherapy, J Clin Oncol, 2004. 22(3): p. 464-7.

291. Vogelzang, N.J., Fraley, E.E., Lange, P.H., Torkelson, J., Levitt, S., Kennedy, B.J., Stage II nonseminomatous testicular cancer: a 10-year experience, J Clin Oncol, 1983. 1(3): p. 171-8.

292. Horwich, A., Norman, A., Fisher, C., Hendry, W.F., Nicholls, J., Dearnaley, D.P., Primary chemotherapy for stage II nonseminomatous germ cell tumors of the testis, J Urol, 1994. 151(1): p. 72-7; discussion 77-8.

293. Donohue, J.P., Roth, L.M., Zachary, J.M., Rowland, R.G., Einhorn, L.H., Williams, S.G., Cytoreductive surgery for metastatic testis cancer: tissue analysis of retroperitoneal masses after chemotherapy, J Urol, 1982. 127(6): p. 1111-4.

294. Weissbach, L., Boedefeld, E.A., Localization of solitary and multiple metastases in stage II nonseminomatous testis tumor as basis for a modified staging lymph node dissection in stage I, J Urol, 1987. 138(1): p. 77-82.

295. Eggener, S.E., Carver, B.S., Sharp, D.S., Motzer, R.J., Bosl, G.J., Sheinfeld, J., Incidence of disease outside modified retroperitoneal lymph node dissection templates in clinical stage I or IIA nonseminomatous germ cell testicular cancer, J Urol, 2007b. 177(3): p. 937-42; discussion 942-3.

296. Behnia, M., Foster, R., Einhorn, L.H., Donohue, J., Nichols, C.R., Adjuvant bleomycin, etoposide and cisplatin in pathological stage II non-seminomatous testicular cancer. the Indiana University experience, Eur J Cancer, 2000. 36(4): p. 472-5.

297. Fossa, S.D., Kaye, S.B., Mead, G.M., Cullen, M., de Wit, R., Bodrogi, I., et.al. Filgrastim during combination chemotherapy of patients with poor-prognosis metastatic germ cell malignancy. European Organization for Research and Treatment of Cancer, Genito-Urinary Group, and the Medical Research Council Testicular Cancer Working Party, Cambridge, United Kingdom, J Clin Oncol, 1998. 16(2): p. 716-24.

298. Cullen, M., Steven, N., Billingham, L., Gaunt, C., Hastings, M., Simmonds, P., et.al. Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas, N Engl J Med, 2005. 353(10): p. 988-98.

299. Culine, S., Kerbrat, P., Kramar, A., Theodore, C., Chevreau, C., Geoffrois, L., et.al. Refining the optimal chemotherapy regimen for good-risk metastatic nonseminomatous germ-cell tumors: a randomized trial of the Genito-Urinary Group of the French Federation of Cancer Centers (GETUG T93BP), Ann Oncol, 2007. 18(5): p. 917-24.

300. Toner, G.C., Stockler, M.R., Boyer, M.J., Jones, M., Thomson, D.B., Harvey, V.J., et.al. Comparison of two standard chemotherapy regimens for good-prognosis germ-cell tumours: a randomised trial. Australian and New Zealand Germ Cell Trial Group, Lancet, 2001. 357(9258): p. 739-45.

301. Grimison, P.S., Stockler, M.R., Thomson, D.B., Olver, I.N., Harvey, V.J., Gebski, V.J., et.al. Comparison of two standard chemotherapy regimens for good-prognosis germ cell tumors: updated analysis of a randomized trial, J Natl Cancer Inst, 2010. 102(16): p. 1253-62.

302. Einhorn, L.H., Donohue, J., Cis-diamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer, Ann Intern Med, 1977. 87(3): p. 293-8.

303. de Wit, R., Refining the optimal chemotherapy regimen in good prognosis germ cell cancer: interpretation of the current body of knowledge, J Clin Oncol, 2007. 25(28): p. 4346-9.

304. Fizazi, K., Pagliaro, L., Laplanche, A., Flechon, A., Mardiak, J., Geoffrois, L., et.al. Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial, Lancet Oncol, 2014b. 15(13): p. 1442-50.

305. Kondagunta, G.V., Bacik, J., Bajorin, D., Dobrzynski, D., Sheinfeld, J., Motzer, R.J., et.al. Etoposide and cisplatin chemotherapy for metastatic good-risk germ cell tumors, J Clin Oncol, 2005. 23(36): p. 9290-4.

306. Thibault, C., Fizazi, K., Barrios, D., Massard, C., Albiges, L., Baumert, H., et.al. Compliance with guidelines and correlation with outcome in patients with advanced germ-cell tumours, Eur J Cancer, 2014. 50(7): p. 1284-90.

307. de Wit, R., Stoter, G., Sleijfer, D.T., Neijt, J. P., ten Bokkel Huinink, W.W., de Prijck, L., et.al. Four cycles of BEP vs four cycles of VIP in patients with intermediate-prognosis metastatic testicular non-seminoma: a randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group. European Organization for Research and Treatment of Cancer, Br J Cancer, 1998. 78(6): p. 828-32.

308. de Wit, R., Roberts, J.T., Wilkinson, P.M., de Mulder, P.H., Mead, G.M., Fossa, S.D., et.al. Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3- or 5-day schedule in good-prognosis germ cell cancer: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council, J Clin Oncol, 2001. 19(6): p. 1629-40.

309. Leitlinienprogramm Onkologie, Leitlinienprogramm Onkologie (DKG, DKH, AWMF). Supportive Therapie bei onkologischen PatientInnen, Langversion 1.1, AWMF-Registernummer: 032/054OL http://www.awmf.org/uploads/tx_szleitlinien/032-054OLl_S3_Supportiv_2017-05.pdf (Zugriff am 12.12.2017), 2017a.

310. Feuer, E.J., Sheinfeld, J., Bosl, G.J., Does size matter? Association between number of patients treated and patient outcome in metastatic testicular cancer, J Natl Cancer Inst, 1999. 91(10): p. 816-8.

311. Geldart, T.R., Simmonds, P.D., Mead, G.M., Orchidectomy after chemotherapy for patients with metastatic testicular germ cell cancer, BJU Int, 2002. 90(4): p. 451-5.

312. Leibovitch, I., Little, J. S., Jr., Foster, R. S., Rowland, R. G., Bihrle, R., Donohue, J. P., Delayed orchiectomy after chemotherapy for metastatic nonseminomatous germ cell tumors, J Urol, 1996. 155(3): p. 952-4.

313. Ondrus, D., Hornak, M., Breza, J., Mat'oska, J., Schnorrer, M., Belan, V., et.al. Delayed orchiectomy after chemotherapy in patients with advanced testicular cancer, Int Urol Nephrol, 2001. 32(4): p. 665-7.

314. Bokemeyer, C., Kollmannsberger, C., Stenning, S., Hartmann, J.T., Horwich, A., Clemm, C., et.al. Metastatic seminoma treated with either single agent carboplatin or cisplatin-based combination chemotherapy: a pooled analysis of two randomised trials, Br J Cancer, 2004. 91(4): p. 683-7.

315. Calabro, F., Albers, P., Bokemeyer, C., Martin, C., Einhorn, L.H., Horwich, A., et.al. The contemporary role of chemotherapy for advanced testis cancer: a systematic review of the literature, Eur Urol, 2012. 61(6): p. 1212-21.

316. Beyer, J., Bokemeyer, C., [Chemotherapy for germ cell cancer], Urologe A, 2004. 43(12): p. 1507-13.

317. de Wit, R., Skoneczna, I., Daugaard, G., De Santis, M., Garin, A., Aass, N., et.al. Randomized phase III study comparing paclitaxel-bleomycin, etoposide, and cisplatin (BEP) to standard BEP in intermediate-prognosis germ-cell cancer: intergroup study EORTC 30983, J Clin Oncol, 2012. 30(8): p. 792-9.

318. Seidel, C., Daugaard, G., Tryakin, A., Necchi, A., Cohn Cedermark, G., Stahl, O., et.al. Intermediate prognosis in metastatic germ cell tumours-outcome and prognostic factors, Eur J Cancer, 2018. 94: p. 16-25.

319. Cary, C., Pedrosa, J.A., Jacob, J., Beck, S.D., Rice, K.R., Einhorn, L.H., et.al. Outcomes of postchemotherapy retroperitoneal lymph node dissection following high-dose chemotherapy with stem cell transplantation, Cancer, 2015. 121(24): p. 4369-75.

320. Cary, C., Jacob, J. M., Albany, C., Masterson, T. A., Hanna, N. H., Einhorn, L. H., et.al. Long-Term Survival of Good-Risk Germ Cell Tumor Patients After Postchemotherapy Retroperitoneal Lymph Node Dissection: A Comparison of BEP x 3 vs. EP x 4 and Treating Institution, Clin Genitourin Cancer, 2018. 16(2): p. e307-e313.

321. Horwich, A., Sleijfer, D.T., Fossa, S.D., Kaye, S.B., Oliver, R.T., Cullen, M.H., et.al. Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a Multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial, J Clin Oncol, 1997. 15(5): p. 1844-52.

322. Nichols, C.R., Catalano, P.J., Crawford, E.D., Vogelzang, N.J., Einhorn, L.H., Loehrer, P.J., Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: an Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B Study, J Clin Oncol, 1998. 16(4): p. 1287-93.

323. Bokemeyer, C., Kollmannsberger, C., Meisner, C., Harstrick, A., Beyer, J., Metzner, B., et.al. First-line high-dose chemotherapy compared with standard-dose PEB/VIP chemotherapy in patients with advanced germ cell tumors: A multivariate and matched-pair analysis, J Clin Oncol, 1999b. 17(11): p. 3450-6.

324. Oechsle, K., Bokemeyer, C., Kollmannsberger, C., Mayer, F., Berger, L. A., Oing, C., et.al. Bone metastases in germ cell tumor patients, J Cancer Res Clin Oncol, 2012. 138(6): p. 947-52.

325. Oing, C., Oechsle, K., Necchi, A., Loriot, Y., De Giorgi, U., Flechon, A., et.al. Impact of primary metastatic bone disease in germ cell tumors: results of an International Global Germ Cell Tumor Collaborative Group G3 Registry Study, Ann Oncol, 2017. 28(3): p. 576-582.

326. Feldman, D.R., Lorch, A., Kramar, A., Albany, C., Einhorn, L.H., Giannatempo, P., et.al. Brain metastases in patients with germ cell tumors: prognostic factors and treatment options-an analysis from the global germ cell cancer group, J Clin Oncol, 2016. 34(4): p. 345-51.

327. Daugaard, G., Skoneczna, I., Aass, N., De Wit, R., De Santis, M., Dumez, H., et.al. A randomized phase III study comparing standard dose BEP with sequential high-dose cisplatin, etoposide, and ifosfamide (VIP) plus stem-cell support in males with poor-prognosis germ-cell cancer. An intergroup study of EORTC, GTCSG, and Grupo Germinal (EORTC 30974), Ann Oncol, 2011. 22(5): p. 1054-61.

328. Motzer, R.J., Nichols, C.J., Margolin, K.A., Bacik, J., Richardson, P.G., Vogelzang, N.J., et.al. Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors, J Clin Oncol, 2007. 25(3): p. 247-56.

329. Droz, J.P., Kramar, A., Biron, P., Pico, J.L., Kerbrat, P., Peny, J., et.al. Failure of high-dose cyclophosphamide and etoposide combined with double-dose cisplatin and bone marrow support in patients with high-volume metastatic nonseminomatous germ-cell tumours: mature results of a randomised trial, Eur Urol, 2007. 51(3): p. 739-46; discussion 747-8.

330. Schmoll, H.J., Kollmannsberger, C., Metzner, B., Hartmann, J. T., Schleucher, N., Schoffski, P., et.al. Long-term results of first-line sequential high-dose etoposide, ifosfamide, and cisplatin chemotherapy plus autologous stem cell support for patients with advanced metastatic germ cell cancer: an extended phase I/II study of the German Testicular Cancer Study Group, J Clin Oncol, 2003. 21(22): p. 4083-91.

331. Fizazi, K., Delva, R., Caty, A., Chevreau, C., Kerbrat, P., Rolland, F., et.al. A risk-adapted study of cisplatin and etoposide, with or without ifosfamide, in patients with metastatic seminoma: results of the GETUG S99 multicenter prospective study, Eur Urol, 2014a. 65(2): p. 381-6.

332. Bokemeyer, C., Nichols, C.R., Droz, J.P., Schmoll, H.J., Horwich, A., Gerl, A., et.al. Extragonadal germ cell tumors of the mediastinum and retroperitoneum: results from an international analysis, J Clin Oncol, 2002. 20(7): p. 1864-73.

333. Fizazi, K., Culine, S., Kramar, A., Amato, R.J., Bouzy, J., Chen, I., et.al. Early predicted time to normalization of tumor markers predicts outcome in poor-prognosis nonseminomatous germ cell tumors, J Clin Oncol, 2004b. 22(19): p. 3868-76.

334. Toner, G.C., Geller, N.L., Tan, C., Nisselbaum, J., Bosl, G.J., Serum tumor marker half-life during chemotherapy allows early prediction of complete response and survival in nonseminomatous germ cell tumors, Cancer Res, 1990. 50(18): p. 5904-10.

335. Mazumdar, M., Bajorin, D. F., Bacik, J., Higgins, G., Motzer, R. J., Bosl, G. J., Predicting outcome to chemotherapy in patients with germ cell tumors: the value of the rate of decline of human chorionic gonadotrophin and alpha-fetoprotein during therapy, J Clin Oncol, 2001. 19(9): p. 2534-41.

336. Oechsle, K., Kollmannsberger, C., Honecker, F., Boehlke, I., Bokemeyer, C., Cerebral metastases in non-seminomatous germ cell tumour patients undergoing primary high-dose chemotherapy, Eur J Cancer, 2008b. 44(12): p. 1663-9.

337. Girones, R., Aparicio, J., Roure, P., Germa-Lluch, J. R., Garcia Del Muro, X., Vazquez-Estevez, S., et.al. Synchronous versus metachronous brain metastasis from testicular germ cell tumors (TGCT): an analysis from the Spanish Germ Cell Cancer Group data base, Clin Transl Oncol, 2014. 16(11): p. 959-65.

338. Bokemeyer, C., Nowak, P., Haupt, A., Metzner, B., Kohne, H., Hartmann, J.T., et.al. Treatment of brain metastases in patients with testicular cancer, J Clin Oncol, 1997. 15(4): p. 1449-54.

339. Kollmannsberger, C., Nichols, C., Bamberg, M., Hartmann, J. T., Schleucher, N., Beyer, J., et.al. First-line high-dose chemotherapy +/- radiation therapy in patients with metastatic germ-cell cancer and brain metastases, Ann Oncol, 2000a. 11(5): p. 553-9.

340. Hardt, A., Krell, J., Wilson, P.D., Harding, V., Chowdhury, S., Mazhar, D., et.al. Brain metastases associated with germ cell tumors may be treated with chemotherapy alone, Cancer, 2014. 120(11): p. 1639-46.

341. Doyle, D.M., Einhorn, L.H., Delayed effects of whole brain radiotherapy in germ cell tumor patients with central nervous system metastases, Int J Radiat Oncol Biol Phys, 2008. 70(5): p. 1361-4.

342. Nini, A., Konieczny, M., Winter, C., Lusch, A., Krauspe, R., Albers, P., Surgical management and outcomes of patients with bone metastases in germ cell tumors: A case series, Urol Oncol, 2018. 36(2): p. 82.e1-82.e5.

343. Froehner, M., Aikele, P., Beuthien-Baumann, B., Kittner, T., Oehlschlaeger, S., Wirth, M. P., Magnetic resonance imaging of bone metastases in patients with nonseminomatous germ cell tumors, Urol Oncol, 2007. 25(3): p. 201-6.

344. Jamal-Hanjani, M., Karpathakis, A., Kwan, A., Mazhar, D., Ansell, W., Shamash, J., et.al. Bone metastases in germ cell tumours: lessons learnt from a large retrospective study, BJU Int, 2013. 112(2): p. 176-81.

345. de Wit, R., Stoter, G., Kaye, S.B., Sleijfer, D.T., Jones, W.G., ten Bokkel Huinink, W.W., et.al. Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group, J Clin Oncol, 1997. 15(5): p. 1837-43.

346. Lauritsen, J., Kier, M. G., Bandak, M., Mortensen, M. S., Thomsen, F. B., Mortensen, J., et.al. Pulmonary function in patients with germ cell cancer treated with bleomycin, etoposide, and cisplatin, J Clin Oncol, 2016. 34(13): p. 1492-9.

347. O'Sullivan, J. M., Huddart, R. A., Norman, A. R., Nicholls, J., Dearnaley, D. P., Horwich, A., Predicting the risk of bleomycin lung toxicity in patients with germ-cell tumours, Ann Oncol, 2003. 14(1): p. 91-6.

348. Shippee, B.M., Bates, J.S., Richards, K.L., The role of screening and monitoring for bleomycin pulmonary toxicity, J Oncol Pharm Pract, 2016. 22(2): p. 308-12.

349. Haugnes, H.S., Aass, N., Fossa, S.D., Dahl, O., Brydoy, M., Aasebo, U., et.al. Pulmonary function in long-term survivors of testicular cancer, J Clin Oncol, 2009. 27(17): p. 2779-86.

350. Haugnes, H.S., Oldenburg, J., Bremnes, R.M., Pulmonary and cardiovascular toxicity in long-term testicular cancer survivors, Urol Oncol, 2015. 33(9): p. 399-406.

351. Bajorin, D.F., Sarosdy, M.F., Pfister, D.G., Mazumdar, M., Motzer, R.J., Scher, H.I., et.al. Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: a multiinstitutional study, J Clin Oncol, 1993. 11(4): p. 598-606.

352. Bokemeyer, C., Kohrmann, O., Tischler, J., Weissbach, L., Rath, U., Haupt, A., et.al. A randomized trial of cisplatin, etoposide and bleomycin (PEB) versus carboplatin, etoposide and bleomycin (CEB) for patients with 'good-risk' metastatic non-seminomatous germ cell tumors, Ann Oncol, 1996b. 7(10): p. 1015-21.

353. Goedert, J.J., Cote, T.R., Virgo, P., Scoppa, S.M., Kingma, D.W., Gail, M.H., et.al. Spectrum of AIDS-associated malignant disorders, Lancet, 1998. 351(9119): p. 1833-9.

354. Lyter, D.W., Bryant, J., Thackeray, R., Rinaldo, C.R., Kingsley, L.A., Incidence of human immunodeficiency virus-related and nonrelated malignancies in a large cohort of homosexual men, J Clin Oncol, 1995. 13(10): p. 2540-6.

355. Goedert, J.J., Purdue, M.P., McNeel, T.S., McGlynn, K.A., Engels, E.A., Risk of germ cell tumors among men with HIV/acquired immunodeficiency syndrome, Cancer Epidemiol Biomarkers Prev, 2007. 16(6): p. 1266-9.

356. Helleberg, M., Gerstoft, J., Afzal, S., Kronborg, G., Larsen, C. S., Pedersen, C., et.al. Risk of cancer among HIV-infected individuals compared to the background population: impact of smoking and HIV, Aids, 2014. 28(10): p. 1499-508.

357. Bernardi, D., Salvioni, R., Vaccher, E., Repetto, L., Piersantelli, N., Marini, B., et.al. Testicular germ cell tumors and human immunodeficiency virus infection: a report of 26 cases. Italian Cooperative Group on AIDS and Tumors, J Clin Oncol, 1995. 13(11): p. 2705-11.

358. Fizazi, K., Amato, R. J., Beuzeboc, P., Petit, N., Bouhour, D., Thiss, A., et.al. Germ cell tumors in patients infected by the human immunodeficiency virus, Cancer, 2001b. 92(6): p. 1460-7.

359. Hentrich, M.U., Brack, N.G., Schmid, P., Schuster, T., Clemm, C., Hartenstein, R.C., Testicular germ cell tumors in patients with human immunodeficiency virus infection, Cancer, 1996. 77(10): p. 2109-16.

360. Powles, T., Bower, M., Daugaard, G., Shamash, J., De Ruiter, A., Johnson, M., et.al. Multicenter study of human immunodeficiency virus-related germ cell tumors, J Clin Oncol, 2003. 21(10): p. 1922-7.

361. Timmerman, J.M., Northfelt, D.W., Small, E.J., Malignant germ cell tumors in men infected with the human immunodeficiency virus: natural history and results of therapy, J Clin Oncol, 1995. 13(6): p. 1391-7.

362. Powles, T., Bower, M., Shamash, J., Stebbing, J., Ong, J., Daugaard, G., et.al. Outcome of patients with HIV-related germ cell tumours: a case-control study, Br J Cancer, 2004. 90(8): p. 1526-30.

363. Berretta, M., Caraglia, M., Martellotta, F., Zappavigna, S., Lombardi, A., Fierro, C., et.al. Drug-drug interactions based on pharmacogenetic profile between highly active antiretroviral therapy and antiblastic chemotherapy in cancer patients with HIV infection, Front Pharmacol, 2016. 7: p. 71.

364. Makinson, A., Pujol, J. L., Le Moing, V., Peyriere, H., Reynes, J., Interactions between cytotoxic chemotherapy and antiretroviral treatment in human immunodeficiency virus-infected patients with lung cancer, J Thorac Oncol, 2010. 5(4): p. 562-71.

365. Passos-Coelho, J. L., Castro Ribeiro, M., Santos, E., Sousa Pontes, C., Brito, B., Miranda, A. C., Suboptimal survival of male germ-cell tumors in southern Portugal--a population-based retrospective study for cases diagnosed in 1999 and 2000, Ann Oncol, 2011. 22(5): p. 1215-20.

366. Gerl, A., Clemm, C., Lamerz, R., Mann, K., Wilmanns, W., Prognostic implications of tumour marker analysis in non-seminomatous germ cell tumours with poor prognosis metastatic disease, Eur J Cancer, 1993. 29a(7): p. 961-5.

367. Murphy, B. A., Motzer, R. J., Mazumdar, M., Vlamis, V., Nisselbaum, J., Bajorin, D., et.al. Serum tumor marker decline is an early predictor of treatment outcome in germ cell tumor patients treated with cisplatin and ifosfamide salvage chemotherapy, Cancer, 1994. 73(10): p. 2520-6.

368. Sheinfeld, J., Bajorin, D., Solomon, M., Management of postchemotherapy residual masses in advanced germ cell tumours, 1997. 17: p. 18-24.

369. Daneshmand, S., Albers, P., Fossa, S.D., Heidenreich, A., Kollmannsberger, C., Krege, S., et.al. Contemporary management of postchemotherapy testis cancer, Eur Urol, 2012. 62(5): p. 867-76.

370. Treglia, G., Sadeghi, R., Annunziata, S., Caldarella, C., Bertagna, F., Giovanella, L., Diagnostic performance of fluorine-18-fluorodeoxyglucose positron emission tomography in the postchemotherapy management of patients with seminoma: systematic review and meta-analysis, Biomed Res Int, 2014. 2014: p. 852681.

371. Loehrer, P.J., Sr., Birch, R., Williams, S.D., Greco, F.A., Einhorn, L.H., Chemotherapy of metastatic seminoma: the Southeastern Cancer Study Group experience, J Clin Oncol, 1987. 5(8): p. 1212-20.

372. De Santis, M., Becherer, A., Bokemeyer, C., Stoiber, F., Oechsle, K., Sellner, F., et.al. 2-18fluoro-deoxy-D-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: an update of the prospective multicentric SEMPET trial, J Clin Oncol, 2004. 22(6): p. 1034-9.

373. Decoene, J., Winter, C., Albers, P., False-positive fluorodeoxyglucose positron emission tomography results after chemotherapy in patients with metastatic seminoma, Urol Oncol, 2015. 33(1): p. 23.e15-23.e21.

374. Pfannenberg, A.C., Oechsle, K., Bokemeyer, C., Kollmannsberger, C., Dohmen, B.M., Bares, R., et.al. The role of [(18)F] FDG-PET, CT/MRI and tumor marker kinetics in the evaluation of post chemotherapy residual masses in metastatic germ cell tumors--prospects for management, World J Urol, 2004. 22(2): p. 132-9.

375. Oechsle, K., Hartmann, M., Brenner, W., Venz, S., Weissbach, L., Franzius, C., et.al. [18F]Fluorodeoxyglucose positron emission tomography in nonseminomatous germ cell tumors after chemotherapy: the German multicenter positron emission tomography study group, J Clin Oncol, 2008a. 26(36): p. 5930-5.

376. Kollmannsberger, C., Oechsle, K., Dohmen, B.M., Pfannenberg, A., Bares, R., Claussen, C.D., et.al. Prospective comparison of [18F]fluorodeoxyglucose positron emission tomography with conventional assessment by computed tomography scans and serum tumor markers for the evaluation of residual masses in patients with nonseminomatous germ cell carcinoma, Cancer, 2002a. 94(9): p. 2353-62.

377. Ehrlich, Y., Brames, M.J., Beck, S.D., Foster, R.S., Einhorn, L.H., Long-term follow-up of Cisplatin combination chemotherapy in patients with disseminated nonseminomatous germ cell tumors: is a postchemotherapy retroperitoneal lymph node dissection needed after complete remission?, J Clin Oncol, 2010. 28(4): p. 531-6.

378. Kollmannsberger, C., Daneshmand, S., So, A., Chi, K.N., Murray, N., Moore, C., et.al. Management of disseminated nonseminomatous germ cell tumors with risk-based chemotherapy followed by response-guided postchemotherapy surgery, J Clin Oncol, 2010b. 28(4): p. 537-42.

379. Hofmockel, G., Gruss, A., Theiss, M., Chemotherapy in advanced seminoma and the role of postcytostatic retroperitoneal lymph node dissection, Urol Int, 1996. 57(1): p. 38-42.

380. Kamat, M.R., Kulkarni, J.N., Tongaonkar, H.B., Ravi, R., Value of retroperitoneal lymph node dissection in advanced testicular seminoma, J Surg Oncol, 1992. 51(1): p. 65-7.

381. Motzer, R., Bosl, G., Heelan, R., Fair, W., Whitmore, W., Sogani, P., et.al. Residual mass: an indication for further therapy in patients with advanced seminoma following systemic chemotherapy, J Clin Oncol, 1987. 5(7): p. 1064-70.

382. Hendry, W.F., Norman, A.R., Dearnaley, D.P., Fisher, C., Nicholls, J., Huddart, R.A., et.al. Metastatic nonseminomatous germ cell tumors of the testis: results of elective and salvage surgery for patients with residual retroperitoneal masses, Cancer, 2002. 94(6): p. 1668-76.

383. Hartmann, J.T., Candelaria, M., Kuczyk, M.A., Schmoll, H.J., Bokemeyer, C., Comparison of histological results from the resection of residual masses at different sites after chemotherapy for metastatic non-seminomatous germ cell tumours, Eur J Cancer, 1997. 33(6): p. 843-7.

384. Sheinfeld, J., The role of adjunctive postchemotherapy surgery for nonseminomatous germ-cell tumors: current concepts and controversies, Semin Urol Oncol, 2002. 20(4): p. 262-71.

385. Steyerberg, E.W., Keizer, H.J., Habbema, J.D., Prediction models for the histology of residual masses after chemotherapy for metastatic testicular cancer. ReHiT Study Group, Int J Cancer, 1999. 83(6): p. 856-9.

386. Rick, O., Bokemeyer, C., Weinknecht, S., Schirren, J., Pottek, T., Hartmann, J. T., et.al. Residual tumor resection after high-dose chemotherapy in patients with relapsed or refractory germ cell cancer, J Clin Oncol, 2004. 22(18): p. 3713-9.

387. Beck, S.D., Foster, R.S., Bihrle, R., Einhorn, L.H., Donohue, J.P., Outcome analysis for patients with elevated serum tumor markers at postchemotherapy retroperitoneal lymph node dissection https://www.ncbi.nlm.nih.gov/pubmed/16135481, J Clin Oncol, 2005. 23(25): p. 6149-56.

388. Ong, T.A., Winkler, M.H., Savage, P.M., Seckl, M.J., Christmas, T.J., Retroperitoneal lymph node dissection after chemotherapy in patients with elevated tumour markers: indications, histopathology and outcome, BJU Int, 2008. 102(2): p. 198-202.

389. Albers, P., Resection of retroperitoneal residual tumor after chemotherapy for testicular cancer indication and surgical techniques, Crit Rev Oncol Hematol, 2004. 50(1): p. 79-85.

390. Albers, P., Ganz, A., Hannig, E., Miersch, W.D., Muller, S.C., Salvage surgery of chemorefractory germ cell tumors with elevated tumor markers, J Urol, 2000. 164(2): p. 381-4.

391. Beck, S.D., Foster, R.S., Bihrle, R., Donohue, J.P., Einhorn, L.H., Is full bilateral retroperitoneal lymph node dissection always necessary for postchemotherapy residual tumor?, Cancer, 2007. 110(6): p. 1235-40.

392. Habuchi, T., Kamoto, T., Hara, I., Kawai, K., Nakao, M., Nonomura, N., et.al. Factors that influence the results of salvage surgery in patients with chemorefractory germ cell carcinomas with elevated tumor markers, Cancer, 2003. 98(8): p. 1635-42.

393. Kobayashi, T., Kawakita, M., Terachi, T., Habuchi, T., Ogawa, O., Kamoto, T., Significance of elevated preoperative alpha-fetoprotein in postchemotherapy residual tumor resection for the disseminated germ cell tumors, J Surg Oncol, 2006. 94(7): p. 619-23.

394. Spiess, P. E., Brown, G. A., Pisters, L. L., Liu, P., Tu, S. M., Evans, J. G., et.al. Viable malignant germ cell tumor in the postchemotherapy retroperitoneal lymph node dissection specimen: can it be predicted using clinical parameters?, Cancer, 2006. 107(7): p. 1503-10.

395. Andre, F., Fizazi, K., Culine, S., Droz, J., Taupin, P., Lhomme, C., et.al. The growing teratoma syndrome: results of therapy and long-term follow-up of 33 patients, Eur J Cancer, 2000. 36(11): p. 1389-94.

396. Fossa, S.D., Stenning, S.P., Gerl, A., Horwich, A., Clark, P.I., Wilkinson, P.M., et.al. Prognostic factors in patients progressing after cisplatin-based chemotherapy for malignant non-seminomatous germ cell tumours, Br J Cancer, 1999. 80(9): p. 1392-9.

397. Zon, R.T., Nichols, C., Einhorn, L.H., Management strategies and outcomes of germ cell tumor patients with very high human chorionic gonadotropin levels, J Clin Oncol, 1998. 16(4): p. 1294-7.

398. Schirren, J., Trainer, S., Eberlein, M., Lorch, A., Beyer, J., Bolukbas, S., The role of residual tumor resection in the management of nonseminomatous germ cell cancer of testicular origin, Thorac Cardiovasc Surg, 2012. 60(6): p. 405-12.

399. Liu, D., Abolhoda, A., Burt, M. E., Martini, N., Bains, M. S., Downey, R. J., et.al. Pulmonary metastasectomy for testicular germ cell tumors: a 28-year experience, Ann Thorac Surg, 1998. 66(5): p. 1709-14.

400. Kesler, K.A., Kruter, L.E., Perkins, S.M., Rieger, K.M., Sullivan, K.J., Runyan, M.L., et.al. Survival after resection for metastatic testicular nonseminomatous germ cell cancer to the lung or mediastinum, Ann Thorac Surg, 2011. 91(4): p. 1085-93; discussion 1093.

401. Andrade, R.S., Kesler, K.A., Wilson, J.L., Brooks, J.A., Reichwage, B.D., Rieger, K.M., et.al. Short- and long-term outcomes after large pulmonary resection for germ cell tumors after bleomycin-combination chemotherapy, Ann Thorac Surg, 2004. 78(4): p. 1224-8; discussion 1228-9.

402. Saxman, S.B., Nichols, C.R., Einhorn, L.H., Pulmonary toxicity in patients with advanced-stage germ cell tumors receiving bleomycin with and without granulocyte colony stimulating factor, Chest, 1997. 111(3): p. 657-60.

403. Besse, B., Grunenwald, D., Flechon, A., Caty, A., Chevreau, C., Culine, S., et.al. Nonseminomatous germ cell tumors: assessing the need for postchemotherapy contralateral pulmonary resection in patients with ipsilateral complete necrosis, J Thorac Cardiovasc Surg, 2009. 137(2): p. 448-52.

404. Tognoni, P.G., Foster, R.S., McGraw, P., Heilman, D., Bihrle, R., Rowland, R.G., et.al. Combined post-chemotherapy retroperitoneal lymph node dissection and resection of chest tumor under the same anesthetic is appropriate based on morbidity and tumor pathology, J Urol, 1998. 159(6): p. 1833-5.

405. Cagini, L., Nicholson, A.G., Horwich, A., Goldstraw, P., Pastorino, U., Thoracic metastasectomy for germ cell tumours: long term survival and prognostic factors, Ann Oncol, 1998. 9(11): p. 1185-91.

406. Fizazi, K., Tjulandin, S., Salvioni, R., Germa-Lluch, J.R., Bouzy, J., Ragan, D., et.al. Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumors: prognostic factors and role of postsurgery chemotherapy--results from an international study group, J Clin Oncol, 2001a. 19(10): p. 2647-57.

407. Pfannschmidt, J., Hoffmann, H., Dienemann, H., Thoracic metastasectomy for nonseminomatous germ cell tumors, J Thorac Oncol, 2010. 5(6 Suppl 2): p. S182-6.

408. Jeldres C., Pham K.N., Daneshmand S., Kollmannsberger C.K., Hayes-Lattin B.M., Wolff E., Odem-Davis K., Porter C.R. and Nichols C.R., Associationof higher institutional volume with improved overall survival in clinical stage III testicular cancer: Results from the National Cancer Data Base (1998-2011)Journal of Clinical Oncology, 2014. 32: p. 4519-19.

409. Mosharafa, A.A., Foster, R.S., Leibovich, B.C., Bihrle, R., Johnson, C., Donohue, J.P., Is post-chemotherapy resection of seminomatous elements associated with higher acute morbidity?, J Urol, 2003. 169(6): p. 2126-8.

410. Carver, B. S., Shayegan, B., Eggener, S., Stasi, J., Motzer, R. J., Bosl, G. J., et.al. Incidence of metastatic nonseminomatous germ cell tumor outside the boundaries of a modified postchemotherapy retroperitoneal lymph node dissection, J Clin Oncol, 2007c. 25(28): p. 4365-9.

411. Fizazi, K., Oldenburg, J., Dunant, A., Chen, I., Salvioni, R., Hartmann, J.T., et.al. Assessing prognosis and optimizing treatment in patients with postchemotherapy viable nonseminomatous germ-cell tumors (NSGCT): results of the sCR2 international study, Ann Oncol, 2008. 19(2): p. 259-64.

412. Carver, B.S., Shayegan, B., Serio, A., Motzer, R.J., Bosl, G.J., Sheinfeld, J., Long-term clinical outcome after postchemotherapy retroperitoneal lymph node dissection in men with residual teratoma, J Clin Oncol, 2007b. 25(9): p. 1033-7.

413. Carver, B.S., Serio, A.M., Bajorin, D., Motzer, R.J., Stasi, J., Bosl, G.J., et.al. Improved clinical outcome in recent years for men with metastatic nonseminomatous germ cell tumors, J Clin Oncol, 2007a. 25(35): p. 5603-8.

414. Winter, C., Pfister, D., Busch, J., Bingol, C., Ranft, U., Schrader, M., et.al. Residual tumor size and IGCCCG risk classification predict additional vascular procedures in patients with germ cell tumors and residual tumor resection: a multicenter analysis of the German Testicular Cancer Study Group, Eur Urol, 2012. 61(2): p. 403-9.

415. Arai, Y., Kaiho, Y., Yamada, S., Saito, H., Mitsuzuka, K., Yamashita, S., et.al. Extraperitoneal laparoscopic retroperitoneal lymph node dissection after chemotherapy for nonseminomatous testicular germ-cell tumor: surgical and oncological outcomes, Int Urol Nephrol, 2012. 44(5): p. 1389-95.

416. Busch, J., Magheli, A., Erber, B., Friedersdorff, F., Hoffmann, I., Kempkensteffen, C., et.al. Laparoscopic and open postchemotherapy retroperitoneal lymph node dissection in patients with advanced testicular cancer--a single center analysis, BMC Urol, 2012. 12: p. 15.

417. Calestroupat, J.P., Sanchez-Salas, R., Cathelineau, X., Rozet, F., Galiano, M., Smyth, G., et.al. Postchemotherapy laparoscopic retroperitoneal lymph node dissection in nonseminomatous germ-cell tumor, J Endourol, 2009. 23(4): p. 645-50.

418. Eggener, S.E., Carver, B.S., Loeb, S., Kondagunta, G.V., Bosl, G.J., Sheinfeld, J., Pathologic findings and clinical outcome of patients undergoing retroperitoneal lymph node dissection after multiple chemotherapy regimens for metastatic testicular germ cell tumors, Cancer, 2007a. 109(3): p. 528-35.

419. Nicolai, N., Necchi, A., Gianni, L., Piva, L., Biasoni, D., Torelli, T., et.al. Long-term results of a combination of paclitaxel, cisplatin and gemcitabine for salvage therapy in male germ-cell tumours, BJU Int, 2009. 104(3): p. 340-6.

420. Oechsle, K., Kollmannsberger, C., Honecker, F., Mayer, F., Waller, C. F., Hartmann, J. T., et.al. Long-term survival after treatment with gemcitabine and oxaliplatin with and without paclitaxel plus secondary surgery in patients with cisplatin-refractory and/or multiply relapsed germ cell tumors, Eur Urol, 2011b. 60(4): p. 850-5.

421. van de Wetering, R.A.W., Sleijfer, S., Feldman, D.R., Funt, S.A., Bosl, G.J., de Wit, R., Controversies in the management of clinical stage I seminoma: carboplatin a decade in-time to start backing out, J Clin Oncol, 2018. 36(9): p. 837-840.

422. Classen, J., Schmidberger, H., Meisner, C., Winkler, C., Dunst, J., Souchon, R., et.al. Para-aortic irradiation for stage I testicular seminoma: results of a prospective study in 675 patients. A trial of the German testicular cancer study group (GTCSG), Br J Cancer, 2004. 90(12): p. 2305-11.

423. Oldenburg, J., Martin, J. M., Fossa, S. D., Late relapses of germ cell malignancies: incidence, management, and prognosis, J Clin Oncol, 2006b. 24(35): p. 5503-11.

424. Lorch, A., Beyer, J., Bascoul-Mollevi, C., Kramar, A., Einhorn, L. H., Necchi, A., et.al. Prognostic factors in patients with metastatic germ cell tumors who experienced treatment failure with cisplatin-based first-line chemotherapy, J Clin Oncol, 2010a. 28(33): p. 4906-11.

425. Lorch, A., Rick, O., Wundisch, T., Hartmann, J. T., Bokemeyer, C., Beyer, J., High dose chemotherapy as salvage treatment for unresectable late relapse germ cell tumors, J Urol, 2010b. 184(1): p. 168-73.

426. Motzer, R.J., Cooper, K., Geller, N.L., Bajorin, D.F., Dmitrovsky, E., Herr, H., et.al. The role of ifosfamide plus cisplatin-based chemotherapy as salvage therapy for patients with refractory germ cell tumors, Cancer, 1990. 66(12): p. 2476-81.

427. Motzer, R. J., Sheinfeld, J., Mazumdar, M., Bains, M., Mariani, T., Bacik, J., et.al. Paclitaxel, ifosfamide, and cisplatin second-line therapy for patients with relapsed testicular germ cell cancer, J Clin Oncol, 2000. 18(12): p. 2413-8.

428. Loehrer, P.J., Sr., Gonin, R., Nichols, C.R., Weathers, T., Einhorn, L.H., Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor, J Clin Oncol, 1998. 16(7): p. 2500-4.

429. Kurobe, M., Kawai, K., Oikawa, T., Ichioka, D., Kandori, S., Takaoka, E., et.al. Paclitaxel, ifosfamide, and cisplatin (TIP) as salvage and consolidation chemotherapy for advanced germ cell tumor, J Cancer Res Clin Oncol, 2015. 141(1): p. 127-33.

430. Mead, G.M., Cullen, M. H., Huddart, R., Harper, P., Rustin, G.J., Cook, P.A., et.al. A phase II trial of TIP (paclitaxel, ifosfamide and cisplatin) given as second-line (post-BEP) salvage chemotherapy for patients with metastatic germ cell cancer: a medical research council trial, Br J Cancer, 2005. 93(2): p. 178-84.

431. Berger, L.A., Bokemeyer, C., Lorch, A., Hentrich, M., Kopp, H.G., Gauler, T.C., et.al. First salvage treatment in patients with advanced germ cell cancer after cisplatin-based chemotherapy: analysis of a registry of the German Testicular Cancer Study Group (GTCSG), J Cancer Res Clin Oncol, 2014. 140(7): p. 1211-20.

432. Pico, J.L., Rosti, G., Kramar, A., Wandt, H., Koza, V., Salvioni, R., et.al. A randomised trial of high-dose chemotherapy in the salvage treatment of patients failing first-line platinum chemotherapy for advanced germ cell tumours, Ann Oncol, 2005. 16(7): p. 1152-9.

433. Einhorn, L.H., Williams, S.D., Chamness, A., Brames, M.J., Perkins, S.M., Abonour, R., High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors, N Engl J Med, 2007. 357(4): p. 340-8.

434. Beyer, J., Stenning, S., Gerl, A., Fossa, S., Siegert, W., High-dose versus conventional-dose chemotherapy as first-salvage treatment in patients with non-seminomatous germ-cell tumors: a matched-pair analysis, Ann Oncol, 2002. 13(4): p. 599-605.

435. Kondagunta, G.V., Bacik, J., Sheinfeld, J., Bajorin, D., Bains, M., Reich, L., et.al. Paclitaxel plus Ifosfamide followed by high-dose carboplatin plus etoposide in previously treated germ cell tumors, J Clin Oncol, 2007. 25(1): p. 85-90.

436. Adra, N., Abonour, R., Althouse, S.K., Albany, C., Hanna, N.H., Einhorn, L.H., High-dose chemotherapy and autologous peripheral-blood stem-cell transplantation for relapsed metastatic germ cell tumors: The Indiana University Experience, J Clin Oncol, 2017. 35(10): p. 1096-1102.

437. Lorch, A., Bascoul-Mollevi, C., Kramar, A., Einhorn, L., Necchi, A., Massard, C., et.al. Conventional-dose versus high-dose chemotherapy as first salvage treatment in male patients with metastatic germ cell tumors: evidence from a large international database, J Clin Oncol, 2011. 29(16): p. 2178-84.

438. Broun, E.R., Nichols, C.R., Tricot, G., Loehrer, P.J., Williams, S.D., Einhorn, L.H., High dose carboplatin/VP-16 plus ifosfamide with autologous bone marrow support in the treatment of refractory germ cell tumors, Bone Marrow Transplant, 1991. 7(1): p. 53-6.

439. Lotz, J. P., Bui, B., Gomez, F., Theodore, C., Caty, A., Fizazi, K., et.al. Sequential high-dose chemotherapy protocol for relapsed poor prognosis germ cell tumors combining two mobilization and cytoreductive treatments followed by three high-dose chemotherapy regimens supported by autologous stem cell transplantation. Results of the phase II multicentric TAXIF trial, Ann Oncol, 2005. 16(3): p. 411-8.

440. Margolin, K.A., Doroshow, J.H., Frankel, P., Chow, W., Leong, L.A., Lim, D., et.al. Paclitaxel-based high-dose chemotherapy with autologous stem cell rescue for relapsed germ cell cancer, Biol Blood Marrow Transplant, 2005. 11(11): p. 903-11.

441. Motzer, R.J., Mazumdar, M., Bosl, G. J., Bajorin, D.F., Amsterdam, A., Vlamis, V., High-dose carboplatin, etoposide, and cyclophosphamide for patients with refractory germ cell tumors: treatment results and prognostic factors for survival and toxicity, J Clin Oncol, 1996. 14(4): p. 1098-105.

442. Nieto, Y., Tu, S. M., Bassett, R., Jones, R. B., Gulbis, A. M., Tannir, N., et.al. Bevacizumab/high-dose chemotherapy with autologous stem-cell transplant for poor-risk relapsed or refractory germ-cell tumors, Ann Oncol, 2015. 26(10): p. 2125-32.

443. Rick, O., Bokemeyer, C., Beyer, J., Hartmann, J. T., Schwella, N., Kingreen, D., et.al. Salvage treatment with paclitaxel, ifosfamide, and cisplatin plus high-dose carboplatin, etoposide, and thiotepa followed by autologous stem-cell rescue in patients with relapsed or refractory germ cell cancer, J Clin Oncol, 2001. 19(1): p. 81-8.

444. Selle, F., Wittnebel, S., Biron, P., Gravis, G., Roubaud, G., Bui, B. N., et.al. A phase II trial of high-dose chemotherapy (HDCT) supported by hematopoietic stem-cell transplantation (HSCT) in germ-cell tumors (GCTs) patients failing cisplatin-based chemotherapy: the multicentric TAXIF II study, Ann Oncol, 2014. 25(9): p. 1775-82.

445. Lorch, A., Kleinhans, A., Kramar, A., Kollmannsberger, C. K., Hartmann, J. T., Bokemeyer, C., et.al. Sequential versus single high-dose chemotherapy in patients with relapsed or refractory germ cell tumors: long-term results of a prospective randomized trial, J Clin Oncol, 2012. 30(8): p. 800-5.

446. Lorch, A., Kollmannsberger, C., Hartmann, J. T., Metzner, B., Schmidt-Wolf, I. G., Berdel, W. E., et.al. Single versus sequential high-dose chemotherapy in patients with relapsed or refractory germ cell tumors: a prospective randomized multicenter trial of the German Testicular Cancer Study Group, J Clin Oncol, 2007. 25(19): p. 2778-84.

447. Heidenreich, A., Ohlmann, C., Hegele, A., Beyer, J., Repeat retroperitoneal lymphadenectomy in advanced testicular cancer, Eur Urol, 2005. 47(1): p. 64-71.

448. McKiernan, J.M., Motzer, R.J., Bajorin, D.F., Bacik, J., Bosl, G.J., Sheinfeld, J., Reoperative retroperitoneal surgery for nonseminomatous germ cell tumor: clinical presentation, patterns of recurrence, and outcome, Urology, 2003. 62(4): p. 732-6.

449. Hitchins, R.N., Philip, P.A., Wignall, B., Newlands, E.S., Begent, R.H., Rustin, G.J., et.al. Bone disease in testicular and extragonadal germ cell tumours, Br J Cancer, 1988. 58(6): p. 793-6.

450. Oing, C., Lorch, A., Bokemeyer, C., Honecker, F., Beyer, J., Berger, L. A., et.al. First salvage treatment of germ cell tumor patients with bone metastases: retrospective analysis of a large international database, J Cancer Res Clin Oncol, 2015. 141(5): p. 923-31.

451. Heidenreich, A., Haidl, F., Paffenholz, P., Pape, C., Neumann, U., Pfister, D., Surgical management of complex residual masses following systemic chemotherapy for metastatic testicular germ cell tumours, Ann Oncol, 2017. 28(2): p. 362-367.

452. Kawahara, T., Kawai, K., Yoshino, T., Ikeda, A., Ishizuka, R., Kandori, S., et.al. The clinical presentation and favorable prognosis of patients with isolated metachronous brain metastasis from germ cell tumors, Jpn J Clin Oncol, 2016. 46(11): p. 1047–1052.

453. Loriot, Y., Pagliaro, L., Flechon, A., Mardiak, J., Geoffrois, L., Kerbrat, P., et.al. Patterns of relapse in poor-prognosis germ-cell tumours in the GETUG 13 trial: Implications for assessment of brain metastases, Eur J Cancer, 2017. 87: p. 140-146.

454. Sharp, D.S., Carver, B.S., Eggener, S.E., Kondagunta, G.V., Motzer, R.J., Bosl, G.J., et.al. Clinical outcome and predictors of survival in late relapse of germ cell tumor, J Clin Oncol, 2008. 26(34): p. 5524-9.

455. Shahidi, M., Norman, A. R., Dearnaley, D. P., Nicholls, J., Horwich, A., Huddart, R. A., Late recurrence in 1263 men with testicular germ cell tumors. Multivariate analysis of risk factors and implications for management, Cancer, 2002. 95(3): p. 520-30.

456. Oldenburg, J., Alfsen, G. C., Waehre, H., Fossa, S.D., Late recurrences of germ cell malignancies: a population-based experience over three decades, Br J Cancer, 2006a. 94(6): p. 820-7.

457. Geldart, T.R., Gale, J., McKendrick, J., Kirby, J., Mead, G., Late relapse of metastatic testicular nonseminomatous germ cell cancer: surgery is needed for cure, BJU Int, 2006. 98(2): p. 353-8.

458. Ronnen, E.A., Kondagunta, G.V., Bacik, J., Marion, S., Bajorin, D.F., Sheinfeld, J., et.al. Incidence of late-relapse germ cell tumor and outcome to salvage chemotherapy, J Clin Oncol, 2005. 23(28): p. 6999-7004.

459. Dieckmann, K.P., Albers, P., Classen, J., De Wit, M., Pichlmeier, U., Rick, O., et.al. Late relapse of testicular germ cell neoplasms: a descriptive analysis of 122 cases, J Urol, 2005. 173(3): p. 824-9.

460. Miller, J.C., Einhorn, L.H., Phase II study of daily oral etoposide in refractory germ cell tumors, Semin Oncol, 1990. 17(1 Suppl 2): p. 36-9.

461. Maroto, P., Huddart, R., Garcia del Muro, X., Horwich, A., Paz Ares, L., Aparicio, J., et.al. Brief report: phase II multicenter study of temozolomide in patients with cisplatin-resistant germ cell tumors, Oncology, 2011. 80(3-4): p. 219-22.

462. Wheeler, B.M., Loehrer, P.J., Williams, S.D., Einhorn, L.H., Ifosfamide in refractory male germ cell tumors, J Clin Oncol, 1986. 4(1): p. 28-34.

463. Bokemeyer, C., Gerl, A., Schoffski, P., Harstrick, A., Niederle, N., Beyer, J., et.al. Gemcitabine in patients with relapsed or cisplatin-refractory testicular cancer, J Clin Oncol, 1999a. 17(2): p. 512-6.

464. Einhorn, L.H., Stender, M.J., Williams, S.D., Phase II trial of gemcitabine in refractory germ cell tumors, J Clin Oncol, 1999. 17(2): p. 509-11.

465. Fizazi, K., Culine, S., Chen, I., Oxaliplatin in non-seminomatous germ-cell tumors, Ann Oncol, 2004a. 15(8): p. 1295.

466. Kollmannsberger, C., Rick, O., Derigs, H.G., Schleucher, N., Schoffski, P., Beyer, J., et.al. Activity of oxaliplatin in patients with relapsed or cisplatin-refractory germ cell cancer: a study of the German Testicular Cancer Study Group, J Clin Oncol, 2002b. 20(8): p. 2031-7.

467. Bokemeyer, C., Beyer, J., Metzner, B., Ruther, U., Harstrick, A., Weissbach, L., et.al. Phase II study of paclitaxel in patients with relapsed or cisplatin-refractory testicular cancer, Ann Oncol, 1996a. 7(1): p. 31-4.

468. Bokemeyer, C., Schmoll, H.J., Natt, F., Knoche, M., Beyer, J., Souchon, R., Preliminary results of a phase I/II trial of paclitaxel in patients with relapsed or cisplatin-refractory testicular cancer, J Cancer Res Clin Oncol, 1994. 120(12): p. 754-7.

469. Motzer, R.J., Bajorin, D.F., Schwartz, L.H., Hutter, H.S., Bosl, G.J., Scher, H.I., et.al. Phase II trial of paclitaxel shows antitumor activity in patients with previously treated germ cell tumors, J Clin Oncol, 1994. 12(11): p. 2277-83.

470. Nazario, A., Amato, R. J., Hutchinson, L., Bui, C., Ellerhorst, J., Logothetis, C. J., Paclitaxel in extensively pretreated nonseminomatous germ cell tumors, Urol Oncol, 1995. 1(5): p. 184-7.

471. Sandler, A.B., Cristou, A., Fox, S., Williams, S.D., Nichols, C.R., Turns, M., et.al. A phase II trial of paclitaxel in refractory germ cell tumors, Cancer, 1998. 82(7): p. 1381-6.

472. Feldman, D.R., Turkula, S., Ginsberg, M.S., Ishill, N., Patil, S., Carousso, M., et.al. Phase II trial of sunitinib in patients with relapsed or refractory germ cell tumors, Invest New Drugs, 2010. 28(4): p. 523-8.

473. Oechsle, K., Honecker, F., Cheng, T., Mayer, F., Czaykowski, P., Winquist, E., et.al. Preclinical and clinical activity of sunitinib in patients with cisplatin-refractory or multiply relapsed germ cell tumors: a Canadian Urologic Oncology Group/German Testicular Cancer Study Group cooperative study, Ann Oncol, 2011a. 22(12): p. 2654-60.

474. Bokemeyer, C., Oechsle, K., Honecker, F., Mayer, F., Hartmann, J.T., Waller, C.F., et.al. Combination chemotherapy with gemcitabine, oxaliplatin, and paclitaxel in patients with cisplatin-refractory or multiply relapsed germ-cell tumors: a study of the German Testicular Cancer Study Group, Ann Oncol, 2008. 19(3): p. 448-53.

475. De Giorgi, U., Rosti, G., Papiani, G., Aieta, M., Fochessati, F., Paoluzzi, L., et.al. Weekly gemcitabine, paclitaxel, oxaliplatin combination chemotherapy in patients with Cisplatin-refractory germ cell tumor: preliminary experience, Am J Clin Oncol, 2004. 27(5): p. 457-60.

476. De Giorgi, U., Rosti, G., Aieta, M., Testore, F., Burattini, L., Fornarini, G., et.al. Phase II study of oxaliplatin and gemcitabine salvage chemotherapy in patients with cisplatin-refractory nonseminomatous germ cell tumor, Eur Urol, 2006. 50(5): p. 1032-8; discussion 1038-9.

477. Kollmannsberger, C., Beyer, J., Liersch, R., Schoeffski, P., Metzner, B., Hartmann, J.T., et.al. Combination chemotherapy with gemcitabine plus oxaliplatin in patients with intensively pretreated or refractory germ cell cancer: a study of the German Testicular Cancer Study Group, J Clin Oncol, 2004. 22(1): p. 108-14.

478. Pectasides, D., Pectasides, M., Farmakis, D., Aravantinos, G., Nikolaou, M., Koumpou, M., et.al. Gemcitabine and oxaliplatin (GEMOX) in patients with cisplatin-refractory germ cell tumors: a phase II study, Ann Oncol, 2004. 15(3): p. 493-7.

479. Oechsle, K., Kollmannsberger, C., Honecker, F., Mayer, F., Waller, C. F., Hartmann, J. T., et.al. Long-term survival after treatment with gemcitabine and oxaliplatin with and without paclitaxel plus secondary surgery in patients with cisplatin-refractory and/or multiply relapsed germ cell tumors, Eur Urol, 2011b. 60(4): p. 850-5.

480. Seidel, C., Oechsle, K., Lorch, A., Dieing, A., Hentrich, M., Hornig, M., et.al. Efficacy and safety of gemcitabine, oxaliplatin, and paclitaxel in cisplatin-refractory germ cell cancer in routine care--Registry data from an outcomes research project of the German Testicular Cancer Study Group, Urol Oncol, 2016. 34(4): p. 167.e21-8.

481. Matveev, V.B., Volkova, M.I., Cherniev, V.A., Figurin, K.M., Mitin, A.V., [Retroperitoneal lymphadenectomy in disseminated non-seminoma germinogenic testicular tumors after chemotherapy in patients with elevated serum tumor markers], Urologiia, 2010. p. 41-7.

482. Maroto, P., Tabernero, J. M., Villavicencio, H., Mesia, R., Marcuello, E., Sole-Balcells, F. J., et.al. Growing teratoma syndrome: experience of a single institution, Eur Urol, 1997. 32(3): p. 305-9.

483. Stella, M., Gandini, A., Meeus, P., Aleksic, I., Flechon, A., Cropet, C., et.al. Retroperitoneal vascular surgery for the treatment of giant growing teratoma syndrome, Urology, 2012. 79(2): p. 365-70.

484. Logothetis, C.J., Samuels, M.L., Trindade, A., Johnson, D.E., The growing teratoma syndrome, Cancer, 1982. 50(8): p. 1629-35.

485. Jeffery, G.M., Theaker, J.M., Lee, A.H., Blaquiere, R.M., Smart, C.J., Mead, G.M., The growing teratoma syndrome, Br J Urol, 1991. 67(2): p. 195-202.

486. Tongaonkar, H.B., Deshmane, V.H., Dalal, A.V., Kulkarni, J.N., Kamat, M.R., Growing teratoma syndrome, J Surg Oncol, 1994. 55(1): p. 56-60.

487. Tonkin, K.S., Rustin, G.J., Wignall, B., Paradinas, F., Bennett, M., Successful treatment of patients in whom germ cell tumour masses enlarged on chemotherapy while their serum tumour markers decreased, Eur J Cancer Clin Oncol, 1989. 25(12): p. 1739-43.

488. Giannatempo, P., Pond, G.R., Sonpavde, G., Albany, C., Loriot, Y., Sweeney, C.J., et.al. Treatment and clinical outcomes of patients with teratoma with somatic-type malignant transformation: an international collaboration, J Urol, 2016. 196(1): p. 95-100.

489. Rice, K.R., Magers, M.J., Beck, S.D., Cary, K.C., Einhorn, L.H., Ulbright, T.M., et.al. Management of germ cell tumors with somatic type malignancy: pathological features, prognostic factors and survival outcomes, J Urol, 2014. 192(5): p. 1403-9.

490. Necchi, A., Colecchia, M., Nicolai, N., Piva, L., Catanzaro, M., Biasoni, D., et.al. Towards the definition of the best management and prognostic factors of teratoma with malignant transformation: a single-institution case series and new proposal, BJU Int, 2011. 107(7): p. 1088-94.

491. Motzer, R.J., Amsterdam, A., Prieto, V., Sheinfeld, J., Murty, V.V., Mazumdar, M., et.al. Teratoma with malignant transformation: diverse malignant histologies arising in men with germ cell tumors, J Urol, 1998. 159(1): p. 133-8.

492. Donadio, A.C., Motzer, R.J., Bajorin, D.F., Kantoff, P.W., Sheinfeld, J., Houldsworth, J., et.al. Chemotherapy for teratoma with malignant transformation, J Clin Oncol, 2003. 21(23): p. 4285-91.

493. El Mesbahi, O., Terrier-Lacombe, M.J., Rebischung, C., Theodore, C., Vanel, D., Fizazi, K., Chemotherapy in patients with teratoma with malignant transformation, Eur Urol, 2007. 51(5): p. 1306-11; discussion 1311-2.

494. Ganjoo, K.N., Foster, R.S., Michael, H., Donohue, J.P., Einhorn, L.H., Germ cell tumor associated primitive neuroectodermal tumors, J Urol, 2001. 165(5): p. 1514-6.

495. Al-Hader, A.A., Jain, A., Al-Nasrallah, N., Einhorn, L.H., Metastatic malignant transformation of teratoma to primitive neuroectodermal tumor (PNET): results with PNET-based chemotherapy, Am J Clin Oncol, 2015. 38(4): p. 364-6.

496. Nicolai, N., Necchi, A., Raggi, D., Biasoni, D., Catanzaro, M., Piva, L., et.al. Clinical outcome in testicular sex cord stromal tumors: testis sparing vs. radical orchiectomy and management of advanced disease, Urology, 2015. 85(2): p. 402-6.

497. Assi, T., Rassy, M., Nassereddine, H., Sader-Ghorra, C., Abadjian, G., Ghosn, M., et.al. Distribution of testicular tumors in Lebanon: a single institution overview, Asian Pac J Cancer Prev, 2015. 16(8): p. 3443-6.

498. Ghazarian, A.A., Trabert, B., Devesa, S.S., McGlynn, K.A., Recent trends in the incidence of testicular germ cell tumors in the United States, Andrology, 2015. 3(1): p. 13-8.

499. Eble, J. N., Spermatocytic seminoma, Hum Pathol, 1994. 25(10): p. 1035-42.

500. Carriere, P., Baade, P., Fritschi, L., Population based incidence and age distribution of spermatocytic seminoma, J Urol, 2007. 178(1): p. 125-8.

501. Masson, P., Etude sur le séminome, Rev Can Biol, 1946. 5(4): p. 361-87.

502. Stang, A., Jansen, L., Trabert, B., Rusner, C., Eberle, A., Katalinic, A., et.al. Survival after a diagnosis of testicular germ cell cancers in Germany and the United States, 2002-2006: a high resolution study by histology and age, Cancer Epidemiol, 2013. 37(4): p. 492-7.

503. Floyd, C., Ayala, A.G., Logothetis, C.J., Silva, E.G., Spermatocytic seminoma with associated sarcoma of the testis, Cancer, 1988. 61(2): p. 409-14.

504. Stang, A., Trabert, B., Wentzensen, N., Cook, M. B., Rusner, C., Oosterhuis, J. W., et.al. Gonadal and extragonadal germ cell tumours in the United States, 1973-2007, Int J Androl, 2012. 35(4): p. 616-25.

505. Rusner, C., Trabert, B., Katalinic, A., Kieschke, J., Emrich, K., Stang, A., Incidence patterns and trends of malignant gonadal and extragonadal germ cell tumors in Germany, 1998-2008, Cancer Epidemiol, 2013. 37(4): p. 370-3.

506. Moran, C.A., Suster, S., Primary germ cell tumors of the mediastinum: I. Analysis of 322 cases with special emphasis on teratomatous lesions and a proposal for histopathologic classification and clinical staging, Cancer, 1997. 80(4): p. 681-90.

507. Bagrodia, A., Lee, B.H., Lee, W., Cha, E.K., Sfakianos, J.P., Iyer, G., et.al. Genetic determinants of cisplatin resistance in patients with advanced germ cell tumors, J Clin Oncol, 2016. 34(33): p. 4000-4007.

508. Hartmann, J.T., Nichols, C.R., Droz, J.P., Horwich, A., Gerl, A., Fossa, S.D., et.al. Hematologic disorders associated with primary mediastinal nonseminomatous germ cell tumors, J Natl Cancer Inst, 2000. 92(1): p. 54-61.

509. Scholz, M., Zehender, M., Thalmann, G. N., Borner, M., Thoni, H., Studer, U. E., Extragonadal retroperitoneal germ cell tumor: evidence of origin in the testis, Ann Oncol, 2002. 13(1): p. 121-4.

510. Kollmannsberger, C., Nichols, C., Meisner, C., Mayer, F., Kanz, L., Bokemeyer, C., Identification of prognostic subgroups among patients with metastatic 'IGCCCG poor-prognosis' germ-cell cancer: an explorative analysis using cart modeling, Ann Oncol, 2000b. 11(9): p. 1115-20.

511. De Latour, B., Fadel, E., Mercier, O., Mussot, S., Fabre, D., Fizazi, K., et.al. Surgical outcomes in patients with primary mediastinal non-seminomatous germ cell tumours and elevated post-chemotherapy serum tumour markers, Eur J Cardiothorac Surg, 2012. 42(1): p. 66-71; discussion 71.

512. Rodney, A.J., Tannir, N.M., Siefker-Radtke, A.O., Liu, P., Walsh, G.L., Millikan, R.E., et.al. Survival outcomes for men with mediastinal germ-cell tumors: the University of Texas M. D. Anderson Cancer Center experience, Urol Oncol, 2012. 30(6): p. 879-85.

513. Sarkaria, I.S., Bains, M.S., Sood, S., Sima, C.S., Reuter, V.E., Flores, R.M., et.al. Resection of primary mediastinal non-seminomatous germ cell tumors: a 28-year experience at Memorial Sloan-Kettering Cancer Center, J Thorac Oncol, 2011. 6(7): p. 1236-41.

514. Bokemeyer, C., Droz, J. P., Horwich, A., Gerl, A., Fossa, S.D., Beyer, J., et.al. Extragonadal seminoma: an international multicenter analysis of prognostic factors and long term treatment outcome, Cancer, 2001. 91(7): p. 1394-401.

515. Dechaphunkul, A., Sakdejayont, S., Sathitruangsak, C., Sunpaweravong, P., Clinical characteristics and treatment outcomes of patients with primary mediastinal germ cell tumors: 10-Years' experience at a single institution with a bleomycin-containing regimen, Oncol Res Treat, 2016. 39(11): p. 688-694.

516. Liu, T.Z., Zhang, D.S., Liang, Y., Zhou, N.N., Gao, H.F., Liu, K.J., et.al. Treatment strategies and prognostic factors of patients with primary germ cell tumors in the mediastinum, J Cancer Res Clin Oncol, 2011. 137(11): p. 1607-12.

517. Eble, J.N., Sauter, G., Epstein, J.I., Sesterhenn, I.A., Pathology and genetics of tumours of the urinary system and male genital organs - WHO histological classification of testis tumours, IARC Press Lyon, 2004. p. 218:212.

518. Kim, I., Young, R.H., Scully, R.E., Leydig cell tumors of the testis. A clinicopathological analysis of 40 cases and review of the literature, Am J Surg Pathol, 1985. 9(3): p. 177-92.

519. Suardi, N., Strada, E., Colombo, R., Freschi, M., Salonia, A., Lania, C., et.al. Leydig cell tumour of the testis: presentation, therapy, long-term follow-up and the role of organ-sparing surgery in a single-institution experience, BJU Int, 2009. 103(2): p. 197-200.

520. McCluggage, W.G., Shanks, J.H., Arthur, K., Banerjee, S.S., Cellular proliferation and nuclear ploidy assessments augment established prognostic factors in predicting malignancy in testicular Leydig cell tumours, Histopathology, 1998. 33(4): p. 361-8.

521. Maizlin, Z. V., Belenky, A., Kunichezky, M., Sandbank, J., Strauss, S., Leydig cell tumors of the testis: gray scale and color Doppler sonographic appearance, J Ultrasound Med, 2004. 23(7): p. 959-64.

522. Lock, G., Schroder, C., Schmidt, C., Anheuser, P., Loening, T., Dieckmann, K. P., Contrast-enhanced ultrasound and real-time elastography for the diagnosis of benign Leydig cell tumors of the testis - a single center report on 13 cases, Ultraschall Med, 2014. 35(6): p. 534-9.

523. Cheville, J.C., Sebo, T.J., Lager, D.J., Bostwick, D.G., Farrow, G.M., Leydig cell tumor of the testis: a clinicopathologic, DNA content, and MIB-1 comparison of nonmetastasizing and metastasizing tumors, Am J Surg Pathol, 1998. 22(11): p. 1361-7.

524. Matveev, B.P., Gurarii, L.L., [Leydig-cell tumors of the testis], Urol Nefrol (Mosk), 1997. p. 34-6.

525. Bozzini, G., Picozzi, S., Gadda, F., Colombo, R., Decobelli, O., Palou, J., et.al. Long-term follow-up using testicle-sparing surgery for Leydig cell tumor, Clin Genitourin Cancer, 2013. 11(3): p. 321-4.

526. Di Tonno, F., Tavolini, I.M., Belmonte, P., Bertoldin, R., Cossaro, E., Curti, P., et.al. Lessons from 52 patients with leydig cell tumor of the testis: the GUONE (North-Eastern Uro-Oncological Group, Italy) experience, Urol Int, 2009. 82(2): p. 152-7.

527. Leonhartsberger, N., Ramoner, R., Aigner, F., Stoehr, B., Pichler, R., Zangerl, F., et.al. Increased incidence of Leydig cell tumours of the testis in the era of improved imaging techniques, BJU Int, 2011. 108(10): p. 1603-7.

528. Loeser, A., Vergho, D. C., Katzenberger, T., Brix, D., Kocot, A., Spahn, M., et.al. Testis-sparing surgery versus radical orchiectomy in patients with Leydig cell tumors, Urology, 2009. 74(2): p. 370-2.

529. Young, R.H., Koelliker, D.D., Scully, R.E., Sertoli cell tumors of the testis, not otherwise specified: a clinicopathologic analysis of 60 cases, Am J Surg Pathol, 1998. 22(6): p. 709-21.

530. Bremmer, F., Behnes, C.L., Schildhaus, H.U., Gaisa, N.T., Reis, H., Jarry, H., et.al. The role of beta-catenin mutation and SOX9 expression in sex cord-stromal tumours of the testis, Virchows Arch, 2017. 470(4): p. 421-428.

531. Perrone, F., Bertolotti, A., Montemurro, G., Paolini, B., Pierotti, M. A., Colecchia, M., Frequent mutation and nuclear localization of beta-catenin in sertoli cell tumors of the testis, Am J Surg Pathol, 2014. 38(1): p. 66-71.

532. Giglio, M., Medica, M., De Rose, A.F., Germinale, F., Ravetti, J.L., Carmignani, G., Testicular sertoli cell tumours and relative sub-types. Analysis of clinical and prognostic features, Urol Int, 2003. 70(3): p. 205-10.

533. Henley, J.D., Young, R.H., Ulbright, T.M., Malignant Sertoli cell tumors of the testis: a study of 13 examples of a neoplasm frequently misinterpreted as seminoma, Am J Surg Pathol, 2002. 26(5): p. 541-50.

534. Gierke, C.L., King, B.F., Bostwick, D.G., Choyke, P.L., Hattery, R.R., Large-cell calcifying Sertoli cell tumor of the testis: appearance at sonography, AJR Am J Roentgenol, 1994. 163(2): p. 373-5.

535. Featherstone, J.M., Fernando, H.S., Theaker, J.M., Simmonds, P.D., Hayes, M.C., Mead, G.M., Sex cord stromal testicular tumors: a clinical series--uniformly stage I disease, J Urol, 2009. 181(5): p. 2090-6; discussion 2096.

536. Horne, M.J., Adeniran, A.J., Primary diffuse large B-cell lymphoma of the testis, Arch Pathol Lab Med, 2011. 135(10): p. 1363-7.

537. Maganty, A., Fombona, A., Bandari, J., Lyon, T. D., Kulich, S., Gingrich, J. R., et.al. Aggressive surgical management of adenocarcinoma of the rete testis, Urol Case Rep, 2018. 16: p. 72-74.

538. Dieckmann, K.P., Loy, V., Epidermoid cyst of the testis: a review of clinical and histogenetic considerations, Br J Urol, 1994. 73(4): p. 436-41.

539. Semjen, D., Kalman, E., Tornoczky, T., Szuhai, K., Further evidence of the existence of benign teratomas of the postpubertal testis, Am J Surg Pathol, 2014. 38(4): p. 580-1.

540. Zhang, C., Berney, D. M., Hirsch, M. S., Cheng, L., Ulbright, T. M., Evidence supporting the existence of benign teratomas of the postpubertal testis: a clinical, histopathologic, and molecular genetic analysis of 25 cases, Am J Surg Pathol, 2013. 37(6): p. 827-35.

541. Cathomas, R., Helbling, D., Stenner, F., Rothermundt, C., Rentsch, C., Shahin, O., et.al. Interdisciplinary evidence-based recommendations for the follow-up of testicular cancer patients: a joint effort, Swiss Med Wkly, 2010. 140(25-26): p. 356-69.

542. Souchon, R., Hartmann, M., Krege, S., Lorch, A., Mayer, F., De Santis, M., et.al. Interdisciplinary evidence-based recommendations for the follow-up of early stage seminomatous testicular germ cell cancer patients, Strahlenther Onkol, 2011. 187(3): p. 158-66.

543. van As, N. J., Gilbert, D. C., Money-Kyrle, J., Bloomfield, D., Beesley, S., Dearnaley, D. P., et.al. Evidence-based pragmatic guidelines for the follow-up of testicular cancer: optimising the detection of relapse, Br J Cancer, 2008. 98(12): p. 1894-902.

544. Cathomas, R., Hartmann, M., Krege, S., Souchon, R., Lorch, A., Mayer, F., et.al. Interdisciplinary evidence-based recommendations for the follow-up of testicular germ cell cancer patients, Onkologie, 2011. 34(1-2): p. 59-64.

545. Hartmann, M., Krege, S., Souchon, R., De Santis, M., Gillessen, S., Cathomas, R., [Follow-up of testicular germ cell cancer patients: interdisciplinary evidence-based recommendations], Urologe A, 2011. 50(7): p. 830-5.

546. Dohle, G.R., Arver, S., Bettocchi, C., Jones, T.H., Kliesch, S., EAU-Leitlinie Männlicher Hypogonadismus, J Reproduktionsmed Endokrinol_Online, 2018. 15(2): p. 71-88.

547. TRISST, Trial of imaging and schedule in seminoma testis, http://www.ctu.mrc.ac.uk/studies/TE24.a.asp, 2010.

548. Fischer, S., Tandstad, T., Wheater, M., Porfiri, E., Flechon, A., Aparicio, J., et.al. Outcome of men with relapse after adjuvant carboplatin for clinical stage I seminoma, J Clin Oncol, 2017. 35(2): p. 194-200.

549. Aparicio, J., Maroto, P., Garcia del Muro, X., Sanchez-Munoz, A., Guma, J., Margeli, M., et.al. Prognostic factors for relapse in stage I seminoma: a new nomogram derived from three consecutive, risk-adapted studies from the Spanish Germ Cell Cancer Group (SGCCG), Ann Oncol, 2014. 25(11): p. 2173-8.

550. Hoskin, P., Dilly, S., Easton, D., Horwich, A., Hendry, W., Peckham, M. J., Prognostic factors in stage I non-seminomatous germ-cell testicular tumors managed by orchiectomy and surveillance: implications for adjuvant chemotherapy, J Clin Oncol, 1986. 4(7): p. 1031-6.

551. Rustin, G. J., Mead, G. M., Stenning, S. P., Vasey, P. A., Aass, N., Huddart, R. A., et.al. Randomized trial of two or five computed tomography scans in the surveillance of patients with stage I nonseminomatous germ cell tumors of the testis: Medical Research Council Trial TE08, ISRCTN56475197--the National Cancer Research Institute Testis Cancer Clinical Studies Group, J Clin Oncol, 2007. 25(11): p. 1310-5.

552. Nayan, Jewett, M. A., Hosni, A., Anson-Cartwright, L., Bedard, P. L., Moore, M., et.al. Conditional Risk of Relapse in Surveillance for Clinical Stage I testicular Cancer, Eur Urol, 2017. 71(1): p. 120-7.

553. Ko, J., Bernard, B., Tran, B., Li, H., Asif, T., Stukalin, I., et.al. Conditional Survival of Patients With Metastatic Testicular Germ Cell Tumors Treated With First-Line Curative Therapy, J Clin Oncol, 2016. 34(7): p. 714-20.

554. Janssen-Heijnen, M. L., Gondos, A., Bray, F., Hakulinen, T., Brewster, D. H., Brenner, H., et.al. Clinical relevance of conditional survival of cancer patients in europe: age-specific analyses of 13 cancers, J Clin Oncol, 2010. 28(15): p. 2520-8.

555. Shinn, E.H., Swartz, R.J., Thornton, B.B., Spiess, P.E., Pisters, L.L., Basen-Engquist, K.M., Testis cancer survivors' health behaviors: comparison with age-matched relative and demographically matched population controls, J Clin Oncol, 2010. 28(13): p. 2274-9.

556. Leitlinienprogramm Onkologie, Leitlinienprogramm Onkologie (DKG, DKH, AWMF). Supportive Therapie bei onkologischen PatientInnen, Langversion 1.1, AWMF-Registernummer: 032/054OL http://www.awmf.org/uploads/tx_szleitlinien/032-054OLl_S3_Supportiv_2017-05.pdf (Zugriff am 12.12.2017), 2017a.

557. Gizzi, M., Oberic, L., Massard, C., Poterie, A., Gwenael, L. T., Loriot, Y., et.al. Predicting and preventing thromboembolic events in patients receiving cisplatin-based chemotherapy for germ cell tumours, Eur J Cancer, 2016. 69: p. 151-157.

558. Kerns, S. L., Fung, C., Monahan, P. O., Ardeshir-Rouhani-Fard, S., Abu Zaid, M. I., Williams, A. M., et.al. Cumulative Burden of Morbidity Among Testicular Cancer Survivors After Standard Cisplatin-Based Chemotherapy: A Multi-Institutional Study, J Clin Oncol, 2018. p. 20;36(15):1505-1512.

559. Hartmann, J.T., Albrecht, C., Schmoll, H.J., Kuczyk, M.A., Kollmannsberger, C., Bokemeyer, C., Long-term effects on sexual function and fertility after treatment of testicular cancer, Br J Cancer, 1999. 80(5-6): p. 801-7.

560. Jacobsen, K.D., Ous, S., Waehre, H., Trasti, H., Stenwig, A.E., Lien, H.H., et.al. Ejaculation in testicular cancer patients after post-chemotherapy retroperitoneal lymph node dissection, Br J Cancer, 1999. 80(1-2): p. 249-55.

561. Puehse, G., Secker, A., Kemper, S., Hertle, L., Kliesch, S., Testosterone deficiency in testicular germ-cell cancer patients is not influenced by oncological treatment, Int J Androl, 2011. 34(5 Pt 2): p. e351-7.

562. Tuinman, M.A., Fleer, J., Sleijfer, D.T., Hoekstra, H.J., Hoekstra-Weebers, J.E., Marital and sexual satisfaction in testicular cancer survivors and their spouses, Support Care Cancer, 2005. 13(7): p. 540-8.

563. Puehse, G., Wachsmuth, J. U., Kemper, S., Husstedt, I. W., Evers, S., Kliesch, S., Chronic pain has a negative impact on sexuality in testis cancer survivors, J Androl, 2012. 33(5): p. 886-93.

564. Shinn, E.H., Basen-Engquist, K., Thornton, B., Spiess, P.E., Pisters, L., Health behaviors and depressive symptoms in testicular cancer survivors, Urology, 2007. 69(4): p. 748-53.

565. Huddart, R.A., Norman, A., Moynihan, C., Horwich, A., Parker, C., Nicholls, E., et.al. Fertility, gonadal and sexual function in survivors of testicular cancer, Br J Cancer, 2005. 93(2): p. 200-7.

566. Nord, C., Bjoro, T., Ellingsen, D., Mykletun, A., Dahl, O., Klepp, O., et.al. Gonadal hormones in long-term survivors 10 years after treatment for unilateral testicular cancer, Eur Urol, 2003. 44(3): p. 322-8.

567. Puehse, G., Wachsmuth, J. U., Kemper, S., Husstedt, I. W., Kliesch, S., Evers, S., Phantom testis syndrome: prevalence, phenomenology and putative mechanisms, Int J Androl, 2010. 33(1): p. e216-20.

568. Sprauten, M., Brydoy, M., Haugnes, H. S., Cvancarova, M., Bjoro, T., Bjerner, J., et.al. Longitudinal serum testosterone, luteinizing hormone, and follicle-stimulating hormone levels in a population-based sample of long-term testicular cancer survivors, J Clin Oncol, 2014a. 32(6): p. 571-8.

569. Eberhard, J., Stahl, O., Cwikiel, M., Cavallin-Stahl, E., Giwercman, Y., Salmonson, E.C., et.al. Risk factors for post-treatment hypogonadism in testicular cancer patients, Eur J Endocrinol, 2008. 158(4): p. 561-70.

570. de Haas, E.C., Altena, R., Boezen, H.M., Zwart, N., Smit, A.J., Bakker, S.J., et.al. Early development of the metabolic syndrome after chemotherapy for testicular cancer, Ann Oncol, 2013. 24(3): p. 749-55.

571. Haugnes, H.S., Bosl, G.J., Boer, H., Gietema, J.A., Brydoy, M., Oldenburg, J., et.al. Long-term and late effects of germ cell testicular cancer treatment and implications for follow-up, J Clin Oncol, 2012. 30(30): p. 3752-63.

572. Hemminki, K., Liu, H., Sundquist, J., Second cancers after testicular cancer diagnosed after 1980 in Sweden, Ann Oncol, 2010. 21(7): p. 1546-51.

573. Richiardi, L., Scelo, G., Boffetta, P., Hemminki, K., Pukkala, E., Olsen, J. H., et.al. Second malignancies among survivors of germ-cell testicular cancer: a pooled analysis between 13 cancer registries, Int J Cancer, 2007. 120(3): p. 623-31.

574. Travis, L.B., Fossa, S.D., Schonfeld, S.J., McMaster, M.L., Lynch, C.F., Storm, H., et.al. Second cancers among 40,576 testicular cancer patients: focus on long-term survivors, J Natl Cancer Inst, 2005. 97(18): p. 1354-65.

575. van den Belt-Dusebout, A.W., de Wit, R., Gietema, J.A., Horenblas, S., Louwman, M.W., Ribot, J.G., et.al. Treatment-specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer, J Clin Oncol, 2007. 25(28): p. 4370-8.

576. Bokemeyer, C., Schmoll, H. J., Treatment of testicular cancer and the development of secondary malignancies, J Clin Oncol, 1995. 13(1): p. 283-92.

577. Wanderas, E.H., Fossa, S.D., Tretli, S., Risk of subsequent non-germ cell cancer after treatment of germ cell cancer in 2006 Norwegian male patients, Eur J Cancer, 1997. 33(2): p. 253-62.

578. Fung, C., Fossa, S.D., Milano, M.T., Oldenburg, J., Travis, L.B., Solid tumors after chemotherapy or surgery for testicular nonseminoma: a population-based study, J Clin Oncol, 2013. 31(30): p. 3807-14.

579. Howard, R., Gilbert, E., Lynch, C.F., Hall, P., Storm, H., Holowaty, E., et.al. Risk of leukemia among survivors of testicular cancer: a population-based study of 42,722 patients, Ann Epidemiol, 2008. 18(5): p. 416-21.

580. Kollmannsberger, C., Beyer, J., Droz, J. P., Harstrick, A., Hartmann, J. T., Biron, P., et.al. Secondary leukemia following high cumulative doses of etoposide in patients treated for advanced germ cell tumors, J Clin Oncol, 1998a. 16(10): p. 3386-91.

581. Nichols, C.R., Breeden, E.S., Loehrer, P.J., Williams, S.D., Einhorn, L.H., Secondary leukemia associated with a conventional dose of etoposide: review of serial germ cell tumor protocols, J Natl Cancer Inst, 1993. 85(1): p. 36-40.

582. Fossa, S.D., Aass, N., Harvei, S., Tretli, S., Increased mortality rates in young and middle-aged patients with malignant germ cell tumours, Br J Cancer, 2004. 90(3): p. 607-12.

583. Fossa, S.D., Gilbert, E., Dores, G.M., Chen, J., McGlynn, K.A., Schonfeld, S., et.al. Noncancer causes of death in survivors of testicular cancer, J Natl Cancer Inst, 2007. 99(7): p. 533-44.

584. Huddart, R.A., Norman, A., Shahidi, M., Horwich, A., Coward, D., Nicholls, J., et.al. Cardiovascular disease as a long-term complication of treatment for testicular cancer, J Clin Oncol, 2003. 21(8): p. 1513-23.

585. Piketty, A.C., Flechon, A., Laplanche, A., Nouyrigat, E., Droz, J. P., Theodore, C., et.al. The risk of thrombo-embolic events is increased in patients with germ-cell tumours and can be predicted by serum lactate dehydrogenase and body surface area, Br J Cancer, 2005. 93(8): p. 909-14.

586. Alberti, K.G., Zimmet, P., Shaw, J., The metabolic syndrome--a new worldwide definition, Lancet, 2005. 366(9491): p. 1059-62.

587. Haugnes, H.S., Aass, N., Fossa, S.D., Dahl, O., Klepp, O., Wist, E.A., et.al. Components of the metabolic syndrome in long-term survivors of testicular cancer, Ann Oncol, 2007. 18(2): p. 241-8.

588. Rove, K.O., Maroni, P.D., Cost, C.R., Fairclough, D.L., Giannarini, G., Harris, A.K., et.al. Pathologic risk factors for metastatic disease in postpubertal patients with clinical stage I testicular stromal tumors, Urology, 2016. 97: p. 138-144.

589. Sprauten, M., Darrah, T. H., Peterson, D. R., Campbell, M. E., Hannigan, R. E., Cvancarova, M., et.al. Impact of long-term serum platinum concentrations on neuro- and ototoxicity in Cisplatin-treated survivors of testicular cancer, J Clin Oncol, 2012. 30(3): p. 300-7.

590. Feldman, D.R., Ardeshir-Rouhani-Fard, S., Monahan, P., Sesso, H.D., Fung, C., Williams, A.M., et.al. Predicting cardiovascular disease among testicular cancer survivors after modern cisplatin-based chemotherapy: application of the Framingham Risk Score, Clin Genitourin Cancer, 2018. 16(4): p. e761-e769.

591. Heidegger, I., Porres, D., Veek, N., Heidenreich, A., Pfister, D., Predictive factors for developing venous thrombosis during cisplatin-based chemotherapy in testicular cancer, Urol Int, 2017. 99(1): p. 104-109.

592. Srikanthan, A., Tran, B., Beausoleil, M., Jewett, M. A., Hamilton, R. J., Sturgeon, J. F., et.al. Large retroperitoneal lymphadenopathy as a predictor of venous thromboembolism in patients with disseminated germ cell tumors treated with chemotherapy, J Clin Oncol, 2015. 33(6): p. 582-7.

593. Necchi, A., Miceli, R., Oualla, K., Sonpavde, G., Giannatempo, P., Raggi, D., et.al. Effect of Bleomycin Administration on the Development of Pulmonary Toxicity in Patients With Metastatic Germ Cell Tumors Receiving First-Line Chemotherapy: A Meta-Analysis of Randomized Studies, Clin Genitourin Cancer, 2017. 15(2): p. 213-220.e5.

594. Adoue, D., Arlet, P., Bleomycin and Raynaud's phenomenon, Ann Intern Med, 1984. 100(5): p. 770.

595. Teutsch, C., Lipton, A., Harvey, H.A., Raynaud's phenomenon as a side effect of chemotherapy with vinblastine and bleomycin for testicular carcinoma, Cancer Treat Rep, 1977. 61(5): p. 925-6.

596. Vogelzang, N.J., Bosl, G.J., Johnson, K., Kennedy, B.J., Raynaud's phenomenon: a common toxicity after combination chemotherapy for testicular cancer, Ann Intern Med, 1981. 95(3): p. 288-92.

597. Brydoy, M., Oldenburg, J., Klepp, O., Bremnes, R.M., Wist, E. A., Wentzel-Larsen, T., et.al. Observational study of prevalence of long-term Raynaud-like phenomena and neurological side effects in testicular cancer survivors, J Natl Cancer Inst, 2009. 101(24): p. 1682-95.

598. Bauer, C.A., Brozoski, T.J., Cochlear structure and function after round window application of ototoxins, Hear Res, 2005. 201(1-2): p. 121-31.

599. Bokemeyer, C., Berger, C.C., Hartmann, J.T., Kollmannsberger, C., Schmoll, H.J., Kuczyk, M.A., et.al. Analysis of risk factors for cisplatin-induced ototoxicity in patients with testicular cancer, Br J Cancer, 1998. 77(8): p. 1355-62.

600. Osanto, S., Bukman, A., Van Hoek, F., Sterk, P. J., De Laat, J. A., Hermans, J., Long-term effects of chemotherapy in patients with testicular cancer, J Clin Oncol, 1992. 10(4): p. 574-9.

601. Oldenburg, J., Kraggerud, S. M., Cvancarova, M., Lothe, R. A., Fossa, S. D., Cisplatin-induced long-term hearing impairment is associated with specific glutathione s-transferase genotypes in testicular cancer survivors, J Clin Oncol, 2007. 25(6): p. 708-14.

602. Oldenburg, J., Fossa, S.D., Ikdahl, T., Genetic variants associated with cisplatin-induced ototoxicity, Pharmacogenomics, 2008. 9(10): p. 1521-30.

603. Bennett, W.M., Pastore, L., Houghton, D.C., Fatal pulmonary bleomycin toxicity in cisplatin-induced acute renal failure, Cancer Treat Rep, 1980. 64(8-9): p. 921-4.

604. Lauritsen, J., Mortensen, M. S., Kier, M. G., Christensen, I. J., Agerbaek, M., Gupta, R., et.al. Renal impairment and late toxicity in germ-cell cancer survivors, Ann Oncol, 2015. 26(1): p. 173-8.

605. Orre, I.J., Fossa, S.D., Murison, R., Bremnes, R., Dahl, O., Klepp, O., et.al. Chronic cancer-related fatigue in long-term survivors of testicular cancer, J Psychosom Res, 2008. 64(4): p. 363-71.

606. Fossa, S.D., de Wit, R., Roberts, J.T., Wilkinson, P.M., de Mulder, P.H., Mead, G.M., et.al. Quality of life in good prognosis patients with metastatic germ cell cancer: a prospective study of the European Organization for Research and Treatment of Cancer Genitourinary Group/Medical Research Council Testicular Cancer Study Group (30941/TE20), J Clin Oncol, 2003b. 21(6): p. 14(9):1412-8.

607. Sprauten, M., Haugnes, HS., Brydoy, M., Tandstad, T., Langberg, CW., Bjoero, T., et.al. Fatigue in relation to treatment and gonadal function in a population-based sample of 796 testicular cancer survivors 12 and 19 years after treatment, J Clin Oncol, 2014b. 32(15_suppl): p. 4564-4564.

608. Chau, C., Cathomas, R., Wheater, M., Klingbiel, D., Fehr, M., Bennett, J., et.al. Treatment outcome and patterns of relapse following adjuvant carboplatin for stage I testicular seminomatous germ-cell tumour: results from a 17-year UK experience, Ann Oncol, 2015. 26(9): p. 1865-70.

609. Gilbert, E.S., Curtis, R.E., Hauptmann, M., Kleinerman, R.A., Lynch, C.F., Stovall, M., et.al. Stomach cancer following hodgkin lymphoma, testicular cancer and cervical cancer: a pooled analysis of three international studies with a focus on radiation effects, Radiat Res, 2017. 187(2): p. 186-195.

610. Kollmannsberger, C., Hartmann, J.T., Kanz, L., Bokemeyer, C., Risk of secondary myeloid leukemia and myelodysplastic syndrome following standard-dose chemotherapy or high-dose chemotherapy with stem cell support in patients with potentially curable malignancies, J Cancer Res Clin Oncol, 1998b. 124(3-4): p. 207-14.

611. Holzner, B., Efficace, F., Basso, U., Johnson, C.D., Aaronson, N.K., Arraras, J.I., et.al. Cross-cultural development of an EORTC questionnaire to assess health-related quality of life in patients with testicular cancer: the EORTC QLQ-TC26, Qual Life Res, 2013. 22(2): p. 369-78.

612. Koller, M., Neugebauer, E. A., Augustin, M., Bussing, A., Farin, E., Klinkhammer-Schalke, M., et.al. [Assessment of quality of life in health services research - conceptual, methodological and structural prerequisites], Gesundheitswesen, 2009. 71(12): p. 864-72.

613. Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., et.al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology, J Natl Cancer Inst, 1993. 85(5): p. 365-76.

614. O'Leary, M. P., Fowler, F. J., Lenderking, W. R., Barber, B., Sagnier, P. P., Guess, H. A., et.al. A brief male sexual function inventory for urology, Urology, 1995. 46(5): p. 697-706.

615. Ware, JE., Snow, Jr. KK., Kosinski, M., Gandek, B., SF-36 Health Survey: Manual and Interpretation Guide. MA: New England Medical Center, the Health Institute, 1993.

616. Zigmond, A.S., Snaith, R.P., The hospital anxiety and depression scale, Acta Psychiatr Scand, 1983. 67(6): p. 361-70.

617. Cella, D.F., Tulsky, D.S., Gray, G., Sarafian, B., Linn, E., Bonomi, A., et.al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure, J Clin Oncol, 1993. 11(3): p. 570-9.

618. Stoehr, B., Schachtner, L., Pichler, R., Holzner, B., Giesinger, J., Oberguggenberger, A., et.al. Influence of achieved paternity on quality of life in testicular cancer survivors, BJU Int, 2013. 111(4 Pt B): p. E207-12.

619. Bundesarbeitsgemeinschaft, Bundesarbeitsgemeinschaft für Rehabilitation. Arbeitshilfe für die Rehabilitation und Teilhabe von Menschen mit Krebserkrankung, Deutscher Ärzte-Verlag, https://www.bar-frankfurt.de/fileadmin/dateiliste/publikationen/arbeitshilfen/downloads/AH.Krebs.pdf, 2013.

620. G-BA, Gemeinsamer Bundesausschuss. Richtlinie des Gemeinsamen Bundesausschusses über Leistungen zur medizinischen Rehabilitation (Rehabilitations-Richtlinie), veröffentlicht im Bundesanzeiger BAnz AT 03.08.2018 B3., 2016.

621. Rick, O., Oncological Rehabilitation, 2017.

622. Rick, O., Onkologische Rehabilitation als „Initialzünder“, Im Fokus Onkologie, 2016. (4): p. 44-47.

623. Leitlinienprogramm Onkologie, Leitlinienprogramm Onkologie (DKG, DKH, AWMF). Palliativmedizin für Patienten mit einer nicht heilbaren Krebserkrankung, Langversion 1.1, AWMF-Registrierungsnummer: 128/001OL http://www.awmf.org/uploads/tx_szleitlinien/128-001OLl_S3_Palliativmedizin_2015-07.pdf (Zugriff am 12.12.2017), 2015.

624. Rabow, M. W., Dibble, S. L., Pantilat, S. Z., McPhee, S. J., The comprehensive care team: a controlled trial of outpatient palliative medicine consultation, Arch Intern Med, 2004. 164(1): p. 83-91.

625. Temel, J. S., Greer, J. A., Muzikansky, A., Gallagher, E. R., Admane, S., Jackson, V. A., et.al. Early palliative care for patients with metastatic non-small-cell lung cancer, N Engl J Med, 2010. 363(8): p. 733-42.

626. Zimmermann, C., Swami, N., Krzyzanowska, M., Hannon, B., Leighl, N., Oza, A., et.al. Early palliative care for patients with advanced cancer: a cluster-randomised controlled trial, Lancet, 2014. 383(9930): p. 1721-30.

627. Gaertner, J., Wolf, J., Hallek, M., Glossmann, J.P., Voltz, R., Standardizing integration of palliative care into comprehensive cancer therapy--a disease specific approach, Support Care Cancer, 2011. 19(7): p. 1037-43.

628. Gaertner, J., Siemens, W., Meerpohl, J.J., Antes, G., Meffert, C., Xander, C., et.al. Effect of specialist palliative care services on quality of life in adults with advanced incurable illness in hospital, hospice, or community settings: systematic review and meta-analysis, BMJ, 2017. 357: p. j2925.

629. Iversen, K., Oechsle, K., Oing, C., Bokemeyer, C., Seidel, C., Specific characteristics of patients with advanced genitourinary cancer receiving specialized inpatient palliative care, Oncol Res Treat, 2017. 40(10): p. 609-614.

630. Smith, T.J., Temin, S., Alesi, E.R., Abernethy, A.P., Balboni, T.A., Basch, E.M., et.al. American Society of Clinical Oncology provisional clinical opinion: the integration of palliative care into standard oncology care, J Clin Oncol, 2012. 30(8): p. 880-7.

631. Leitlinienprogramm Onkologie, Leitlinienprogramm Onkologie (DKG, DKH, AWMF). Psychoonkologische Diagnostik, Beratung und Behandlung von erwachsenen Krebspatienten, Langversion 1.1, AWMF Registernummer: 032/051OL http://www.awmf.org/uploads/tx_szleitlinien/032-051OLl_S3_Psychoonkologische_Beratung_Behandlung_2014-01_verlaengert.pdf (Zugriff am 12.12.2017), 2014.

632. Leitlinienprogramm Onkologie, Leitlinienprogramm Onkologie (DKG, DKH, AWMF). Diagnostik, Therapie und Nachsorge des Nierenzellkarzinoms, Langversion 1.2, AWMF-Registernummer: 043/017OL. http://www.awmf.org/uploads/tx_szleitlinien/043-017Ol-l_S3_Nierenzellkarzinom_2017-04.pdf (Zugriff am 12.12.2017), 2017b.

633. Weis, J., Psychoonkologie: Konzepte und Aufgaben einer jungen Fachdisziplin, Der Onkologe, 2007. 13(2): p. 185.

634. Kleeberg, U.R., Tews, J.T., Ruprecht, T., Hoing, M., Kuhlmann, A., Runge, C., Patient satisfaction and quality of life in cancer outpatients: results of the PASQOC study, Support Care Cancer, 2005. 13(5): p. 303-10.

635. Sanson-Fisher, R., Girgis, A., Boyes, A., Bonevski, B., Burton, L., Cook, P., The unmet supportive care needs of patients with cancer. Supportive Care Review Group, Cancer, 2000. 88(1): p. 226-37.

636. Baile, W.F., Aaron, J., Patient-physician communication in oncology: past, present, and future, Curr Opin Oncol, 2005. 17(4): p. 331-5.

637. de Haes, H., Teunissen, S., Communication in palliative care: a review of recent literature, Curr Opin Oncol, 2005. 17(4): p. 345-50.

638. Fallowfield, L., Jenkins, V., Communicating sad, bad, and difficult news in medicine, Lancet, 2004. 363(9405): p. 312-9.

639. Fukui, S., Ogawa, K., Ohtsuka, M., Fukui, N., A randomized study assessing the efficacy of communication skill training on patients' psychologic distress and coping: nurses' communication with patients just after being diagnosed with cancer, Cancer, 2008. 113(6): p. 1462-70.

640. Keller, M., Patientenzentrierte Kommunikation in der Onkologie–Erfahrungen mit dem KoMPASS Training, In: WeisJ, Brähler E, Hrsg. Psychoonkologie. Stuttgart: Schattauer; 2012., 2012.

641. Ong, L.M., Visser, M.R., Lammes, F.B., de Haes, J.C., Doctor-patient communication and cancer patients' quality of life and satisfaction, Patient Educ Couns, 2000. 41(2): p. 145-56.

642. Jefford, M., Tattersall, M.H., Informing and involving cancer patients in their own care, Lancet Oncol, 2002. 3(10): p. 629-37.

643. Massie, M.J., Prevalence of depression in patients with cancer, J Natl Cancer Inst Monogr, 2004. p. 57-71.

644. Adler, N.E., Page, A.E.K., The National Academies Collection: Reports funded by National Institutes of Health, in Cancer Care for the Whole Patient: Meeting Psychosocial Health Needs, Setting, Institute of Medicine Committee on Psychosocial Services to Cancer Patients/Families in a Community , Editor. 2008, National Academies Press (US), National Academy of Sciences.: Washington (DC).

645. Keller, M., Sommerfeldt, S., Fischer, C., Knight, L., Riesbeck, M., Lowe, B., et.al. Recognition of distress and psychiatric morbidity in cancer patients: a multi-method approach, Ann Oncol, 2004. 15(8): p. 1243-9.

646. Sharpe, M., Strong, V., Allen, K., Rush, R., Postma, K., Tulloh, A., et.al. Major depression in outpatients attending a regional cancer centre: screening and unmet treatment needs, Br J Cancer, 2004. 90(2): p. 314-20.

647. Stark, D., Kiely, M., Smith, A., Velikova, G., House, A., Selby, P., Anxiety disorders in cancer patients: their nature, associations, and relation to quality of life, J Clin Oncol, 2002. 20(14): p. 3137-48.

648. Zabora, J., Brintzenhofeszoc, K., Curbow, B., Hooker, C., Piantadosi, S., The prevalence of psychological distress by cancer site, Psychooncology, 2001. 10(1): p. 19-28.

649. Zwahlen, D., Hagenbuch, N., Carley, M. I., Recklitis, C. J., Buchi, S., Screening cancer patients' families with the distress thermometer (DT): a validation study, Psychooncology, 2008. 17(10): p. 959-66.

650. Hartung, T.J., Mehnert, A., Friedrich, M., Hartmann, M., Vehling, S., Bokemeyer, C., et.al. Age-related variation and predictors of long-term quality of life in germ cell tumor survivors, Urol Oncol, 2016. 34(2): p. 60.e1-6.

651. Miovic, M., Block, S., Psychiatric disorders in advanced cancer, Cancer, 2007. 110(8): p. 1665-76.

652. Oechsle, K., Hartmann, M., Mehnert, A., Oing, C., Bokemeyer, C., Vehling, S., Symptom burden in long-term germ cell tumor survivors, Support Care Cancer, 2016. 24(5): p. 2243-2250.

653. Vehling, S., Mehnert, A., Hartmann, M., Oing, C., Bokemeyer, C., Oechsle, K., Anxiety and depression in long-term testicular germ cell tumor survivors, Gen Hosp Psychiatry, 2016. 38: p. 21-5.

654. Fallowfield, L., Ratcliffe, D., Jenkins, V., Saul, J., Psychiatric morbidity and its recognition by doctors in patients with cancer, Br J Cancer, 2001. 84(8): p. 1011-5.

655. Newell, S., Sanson-Fisher, R. W., Girgis, A., Bonaventura, A., How well do medical oncologists' perceptions reflect their patients' reported physical and psychosocial problems? Data from a survey of five oncologists, Cancer, 1998. 83(8): p. 1640-51.

656. Sollner, W., DeVries, A., Steixner, E., Lukas, P., Sprinzl, G., Rumpold, G., et.al. How successful are oncologists in identifying patient distress, perceived social support, and need for psychosocial counselling?, Br J Cancer, 2001. 84(2): p. 179-85.

657. Herschbach, P., Screeningverfahren in der Psychoonkologie. Testinstrumente zur Identifikation betreuungsbedürftiger Krebspatienten. Eine Empfehlung der PSO für die psychoonkologische Behandlungspraxis, Deutsche Krebsgesellschaft: Berlin, 2010.

658. Holland, J.C., Bultz, B.D., The NCCN guideline for distress management: a case for making distress the sixth vital sign, J Natl Compr Canc Netw, 2007. 5(1): p. 3-7.

659. NCCN, NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) Distress Management. Version 2.2018. URL: https://www.nccn.org/professionals/physician_gls/pdf/distress.pdf (Zugriff am 03.09.2018), 2018b.

660. Weis, J., Domann, U., [Interventions in the rehabilitation of breast cancer patients--a critical literature review of the state of the art], Rehabilitation (Stuttg), 2006. 45(3): p. 129-45.

661. Whooley, M.A., Avins, A.L., Miranda, J., Browner, W.S., Case-finding instruments for depression. Two questions are as good as many, J Gen Intern Med, 1997. 12(7): p. 439-45.

662. Faller, H., Schuler, M., Richard, M., Heckl, U., Weis, J., Kuffner, R., Effects of psycho-oncologic interventions on emotional distress and quality of life in adult patients with cancer: systematic review and meta-analysis, J Clin Oncol, 2013. 31(6): p. 782-93.

663. Northouse, L.L., Katapodi, M.C., Song, L., Zhang, L., Mood, D.W., Interventions with family caregivers of cancer patients: meta-analysis of randomized trials, CA Cancer J Clin, 2010. 60(5): p. 317-39.

664. (ÄZQ), Ärztliches Zentrum für Qualität in der Medizin, E, Gramsch, JD, Hoppe, G, Jonitz, A, Köhler, al., Ollenschläger G et, Kompendium Q-M-A. Qualitätsmanagement in der ambulanten VersorgungDt. Ärzte-Verl., 2008.

665. Ärztliches Zentrum für Qualität in der Medizin (ÄZQ), Manual Qualitätsindikatoren. Manual für Autoren., 2009. äzq Schriftenreihe: 36:

666. Leitlinienprogramm Onkologie, Leitlinienprogramm Onkologie (DKG, DKH, AWMF). Entwicklung von Leitlinien basierten Qualitätsindikatoren. Methodenpapier für das Leitlinienprogramm Onkologie. Version 2.0., 2017c.